

ACCEPTED PAPER · MAIN TEXT

Bioactive integration and stimuli-responsive therapeutic regulation in additively manufactured metallic orthopedic implants

Paper version: Accepted Paper

Accepted Papers are manuscripts accepted for publication, encompassing all changes made following the peer review process, along with a standard cover page indicating the paper version and an “Accepted Paper” watermark, but excluding any other editing, typesetting or other changes made by AccScience Publishing and/or authors post-acceptance.

Article ID: IJB026220218

Citation: Mao Y, Li Y, Li Y, Chua CK, Li Q, Wang L. Bioactive integration and stimuli-responsive therapeutic regulation in additively manufactured metallic orthopedic implants. *Int J Bioprint*. 2026. doi: 10.36922/IJB026220218

Copyright: © 2026 Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution License, permitting distribution, and reproduction in any medium, provided the original work is properly cited.

Publisher’s Note: AccScience Publishing remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

AccScience Publishing

REVIEW ARTICLE

Volume X Issue X (2026)

doi: 10.36922/IJB026220218

Bioactive integration and stimuli-responsive therapeutic regulation in additively manufactured metallic orthopedic implants

Running title: AM metallic therapeutic orthopedic implants

Yi Mao^{1†}, Yihong Li^{1†}, Yi Li², Chee Kai Chua³, Qi Li^{4*}, and Liqiang Wang^{1*}

¹ State Key Laboratory of Metal Matrix Composites, School of Material Science and Engineering, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Shanghai, 200240, China

² Department of Neurosurgery, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 639 Zhizaoju Street, Shanghai 200011, China

³ Wuhan University of Science and Technology, No. 947 Heping Avenue, Wuhan 430081, Hubei, China

⁴ Department of Orthopedics, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, No. 600 Yishan Road, Shanghai, 200233, China

(This article belongs to the *Special Issue: Intelligent bioprinting: From printable structures to functional systems*)

[†]These authors contributed equally to this work.

*** Corresponding authors:**

Liqiang Wang (wang_liqiang@sjtu.edu.cn)

Qi Li (drlee12@sjtu.edu.cn)

Citation: Mao Y, Li Y, Li Y, Chua CK, Li Q, Wang L. Bioactive integration and stimuli-responsive therapeutic regulation in additively manufactured metallic orthopedic implants. *Int J Bioprint*. 2026. doi: 10.36922/IJB026220218

Received: May 26, 2026

Revised: June 10, 2026

Accepted: July 6, 2026

Published online: July 9, 2026

Copyright: © 2026 Author(s). This is an Open-Access article distributed under the terms of the Creative Commons Attribution License, permitting distribution, and reproduction in any medium, provided the original work is properly cited.

Publisher's Note: AccScience Publishing remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

ACCEPTED PAPER

Abstract

Additive manufacturing (AM) has accelerated the evolution of metallic orthopedic implants from passive structural substitutes toward multifunctional therapeutic platforms. Benefiting from the geometric freedom and compositional flexibility of AM, bioactive substances can be integrated into metallic implants through multiple strategies to regulate the peri-implant microenvironment and improve tissue regeneration. This review summarizes recent advances in bioactive integration and responsive therapeutic release in additively manufactured metallic orthopedic implants. First, major biofunctionalization strategies are discussed, including surface modification, bulk alloying, and structurally integrated reservoirs. These approaches enable the incorporation of antibacterial, osteogenic, angiogenic, and immunomodulatory functions through localized delivery of antibiotics, bioactive ions, peptides, growth factors, and small-molecule therapeutics. Subsequently, recent progress in stimuli-responsive release systems is reviewed, including endogenous stimuli triggered by pH, enzymes, and reactive oxygen species, as well as exogenous regulation through light, magnetic fields, and electrical stimulation, which enable on-demand and microenvironment-adaptive therapy. The relationships among implant architecture, bioactive integration, and dynamic therapeutic regulation are further discussed to highlight the unique advantages of AM in constructing multifunctional implants. Finally, current challenges associated with multifunctional AM metallic implants are discussed, particularly in terms of achieving synergistic biofunctionality, maintaining structural and mechanical integrity under process constraints, ensuring predictable therapeutic release, and establishing reliable process structure property relationships. This review provides insights into the development of intelligent metallic implants capable of simultaneously achieving mechanical support and active therapeutic regulation.

Keywords: Additive manufacturing; Metallic implants; Biofunctionalization; Surface modification; Stimuli-responsive release

1. Introduction

With the increasing prevalence of aging populations, trauma, tumor resection, and infection-associated bone defects, bone repair has become one of the most challenging clinical problems in modern orthopedics.^{1,2} Unlike soft tissues, the regeneration of bone defects requires not only tissue reconstruction but also the restoration of long-term mechanical stability and load-bearing capability. Consequently, for large-volume defects, load-bearing injuries, and complex osteoarticular reconstruction, intrinsic healing alone is often insufficient to achieve satisfactory clinical outcomes.^{3,4} Autografts and allografts remain widely used in clinical practice, yet their limitations have become increasingly evident. Autografts are restricted by donor-site morbidity, limited tissue availability, and prolonged surgical procedures, whereas allografts may lead to immune rejection, pathogen transmission, and long-term integration failure.⁵⁻⁷ Meanwhile, conventional bioceramics and polymeric materials, despite exhibiting certain levels of bioactivity, generally suffer from brittleness, insufficient mechanical strength, and limited long-term stability.⁸ Therefore, the development of advanced orthopedic implants that combine desirable mechanical performance, biocompatibility, and active therapeutic functionality has emerged as a major research focus in bone repair.

An ideal orthopedic implant should not merely provide structural support, but should instead function as a dynamic therapeutic platform capable of actively participating in tissue regeneration and peri-implant microenvironment regulation (See Fig. 1). First, implants must possess mechanical properties compatible with native bone, including an appropriate elastic modulus, high strength, and excellent fatigue resistance, in order to minimize stress shielding and maintain long-term stability.⁹⁻¹¹ Second, implant surfaces and interfaces should exhibit favorable biocompatibility to support cell adhesion, proliferation, and osteogenic differentiation while avoiding severe inflammatory responses, toxic ion release, or uncontrolled corrosion.^{12,13} However, the fulfillment of biomechanical compatibility and biocompatibility alone is no longer sufficient to address increasingly complex clinical demands. Postoperative infection, chronic inflammation, insufficient vascularization, and failed osseointegration remain major causes of implant failure and revision surgery.^{14,15} Consequently, the research focus of orthopedic implants has gradually shifted from passive structural replacement toward active therapeutic regulation. Within this paradigm, implants are increasingly engineered with multifunctional bioactivities, including antibacterial, anti-inflammatory, osteogenic, angiogenic, and localized drug-delivery capabilities, thereby

enabling dynamic intervention throughout the bone-healing process. This transition marks the evolution of orthopedic implants from conventional inert devices toward therapeutic implants.




Figure 1. Characteristics of ideal bone implants. (A) Mechanical compatibility: CT images of cubic and gyroid scaffolds with different pore sizes (i, ii, (a)–(d)). (e) Comparison of simulated and measured Young's modulus within the bone range.¹⁶ (B) Biological activity: (a) Mg-CS/CH bioactivation of AM Ti–6Al–4V scaffolds; (b) Col I and (c) FN secretion by WJMSCs, and (d) their adsorption on the coated surface.¹⁷ (C) Biocompatibility: (a) SEM images of the coated scaffold surface and (b) WJMSCs adhered after 6 and 24 h.¹⁷ (D) Active treatment function: (a)

MICs and inhibition zones of coated implants against four bacteria; (b) 7-day antibacterial durability against *S. epidermidis*.¹⁸ Reprinted with permission from¹⁶, Copyright (2018), MDPI; Reprinted with permission from¹⁷, Copyright (2019), MDPI; Reprinted with permission from¹⁸, Copyright (2025), MDPI.

Metallic materials occupy an irreplaceable position in load-bearing bone repair owing to their excellent mechanical strength, fatigue resistance, and long-term stability.^{16,19} Commonly used metallic biomaterials for orthopedic implants include stainless steels, cobalt–chromium alloys, titanium and titanium alloys, magnesium-based alloys, and zinc-based alloys (See Table 1). Stainless steels and cobalt–chromium alloys provide high strength and wear resistance but may suffer from ion release and stress-shielding effects during long-term implantation.^{20–22} Titanium and titanium alloys have become the most widely used orthopedic metals because of their favorable corrosion resistance, favorable biocompatibility, and relatively low elastic modulus.^{23–25} In contrast, biodegradable magnesium- and zinc-based metals have attracted increasing attention in recent years due to their ability to gradually degrade after bone healing, thereby reducing the need for secondary surgery.^{26–29} Despite their excellent mechanical properties, however, conventional manufacturing approaches often struggle to simultaneously achieve complex structural fabrication, patient-specific customization, and multifunctional integration. In particular, traditional casting, forging, and machining techniques are limited in their ability to precisely fabricate individualized implants with interconnected porosity and graded architectures, which restricts efficient biological integration between implants and host bone.

Table1. Summary of major metallic material systems for orthopedic implants

Material Type	Advantages	Limitations	Application	References
Ti & Ti-based alloys	Excellent corrosion resistance, high biocompatibility, relatively low elastic modulus.	Stress shielding; inherently bio-inert surface.	Load-bearing, permanent or long-term implants	30-32
Stainless steels	High mechanical strength, good ductility, cost-effective, easy to process.	High elastic modulus causing severe stress shielding; risk of toxic ion (Ni, Cr) release	Temporary fixation, cost-sensitive applications	33,34
Co-Cr alloys	Superior wear resistance, excellent high-temperature strength, good corrosion resistance.	Extremely high elastic modulus; potential release of toxic heavy metal ions leading to hypersensitivity	High-wear applications (articulating surfaces in hip/knee joint replacements); resists mechanical	35,36
Mg-based alloys	Elastic modulus is close to human cortical bone; degradation avoids secondary removal surgery; osteo-inductive.	Degradation rate in physiological environment is too rapid; localized hydrogen gas evolution can hinder tissue healing.	Temporary load-bearing implants; degrades in vivo.	37-39

Zn-based alloys	More appropriate degradation rate than Mg; favorable biocompatibility and intrinsic antibacterial ability.	Inferior mechanical strength and ductility compared to standard load-bearing	Temporary implants; degrades at a moderate rate.	40,41
-----------------	--	--	--	-------

The rapid development of additive manufacturing (AM) has provided a new technological route to address these challenges. Unlike conventional subtractive manufacturing, AM fabricates structures layer by layer from digital models, thereby enabling the production of patient-specific implants with highly complex geometries.^{42,43} More importantly, AM allows precise control over porosity, pore size, lattice architecture, and internal channels, enabling improved balance among mechanical performance, nutrient transport, and tissue ingrowth.^{43,44}

Current AM technologies for metallic orthopedic implants mainly include powder bed fusion (PBF), inkjet printing, and extrusion-based printing. Among these, selective laser melting (SLM)⁴⁵⁻⁴⁷ and electron beam melting (EBM)^{48,49}, as representative PBF technologies, have been extensively applied to the high-precision fabrication of titanium and cobalt–chromium alloys. Inkjet printing exhibits advantages in low-temperature processing and complex internal structure construction, making it attractive for certain biodegradable metal systems,^{50,51} whereas extrusion-based printing is more suitable for producing metal scaffolds with high structural integrity.⁵² The emergence of AM has therefore not only transformed the manufacturing process for implants, but also the design concept: implants are no longer just machined metal devices, but integrated therapeutic systems in which structure, composition and function can be engineered together.

With continued advances in the field, strategies based solely on structural optimization have gradually revealed their limitations. Although porous architectures and surface topographies can enhance bone ingrowth and improve biomechanical compatibility, their capacity to actively regulate complex pathological microenvironments remains limited. For instance, postoperative infection may result in bacterial biofilm formation and impaired osseointegration; chronic inflammation can suppress osteogenesis and induce fibrotic encapsulation; and insufficient local vascularization may hinder tissue regeneration.⁵³ These challenges indicate that future implants must possess not only structural compatibility but also therapeutic capability. Against this

background, the integration and release of bioactive substances have emerged as central themes in the development of AM metallic implants. By incorporating antibiotics, therapeutic metal ions, growth factors, peptides, immunomodulatory molecules, and responsive nanomaterials, implants can actively regulate the peri-implant microenvironment to achieve antibacterial activity, immune modulation, angiogenesis, and bone regeneration.^{54,55}

A large number of valuable review studies have emerged, providing important references for the development of different technical approaches. However, the existing literature remains fragmented. For instance, Jing *et al.*⁵⁶ systematically reviewed functionalization strategies for 3D-printed titanium alloys but focused primarily on long-term stability and anti-infection, with limited discussion of therapeutic regulation. Vyavahare *et al.*⁵⁷ and Kechagias *et al.*⁵⁸ concentrated on porosity design and mechanical optimization, overlooking how implants can assume active therapeutic functions. Li *et al.*⁵⁹ and Akay *et al.*⁶⁰ provided comprehensive overviews of antibacterial and osteogenesis coatings yet often separated surface modification from structural design and biological response. Meanwhile, reviews on stimulus-responsive materials, such as that by Zhang *et al.*⁶¹, typically emphasized single triggers without integrating these strategies into the broader design logic of additively manufactured metallic implants. Moreover, with the development of AM technologies, bioactive integration strategies in implants have gradually expanded from simple surface loading toward more complex functionalization modes. The role of implants is also transitioning from traditional passive load-bearing structures toward therapeutic platforms capable of achieving localized treatment, stimuli-response, and microenvironmental regulation. However, existing studies still tend to focus on specific material systems, individual functional modules, or localized release behaviors, while discussions on dynamic release regulation from the perspective of bioactive integration remain relatively limited. Therefore, this review reexamines the development of AM metallic orthopedic implants from the viewpoint of therapeutic implants and bioactive integration, and summarizes recent advances in bioactive integration and dynamic therapeutic regulation.

This review focuses on bioactive integration and therapeutic functionalization in AM metallic orthopedic implants. Unlike reviews that concentrate on isolated aspects such as structural design, surface coatings, or single-stimulus responses, this review takes the integration of bioactive substances as its central theme. It primarily focuses on AM orthopedic implants, particularly Ti and Ti6Al4V systems, as they represent the most extensively studied and clinically relevant

metallic platforms in current orthopedic applications. Other metallic systems, including stainless steels, Co-Cr alloys, Mg-based alloys, and Zn-based alloys, are discussed when directly relevant to specific functionalization strategies. Based on this scope, this review summarizes recent research progress in the bioactive integration and therapeutic regulation of AM metallic orthopedic implants (Fig. 2). First, strategies for introducing biofunctions through bulk alloying, structural reservoirs, and surface functionalization are discussed, with emphasis on antibacterial activity, osteogenic and angiogenic promotion, and localized therapeutic delivery. Subsequently, stimulus-responsive systems designed to regulate therapeutic release in response to pathological microenvironments or exogenous physical cues are reviewed, including endogenous stimulus-responsive platforms triggered by pH, enzymes, and reactive oxygen species (ROS), as well as exogenous regulation approaches based on light, magnetic fields, and electrical stimulation. Finally, current challenges associated with multifunctional AM metallic implants are discussed, particularly in terms of achieving synergistic biofunctionality, maintaining structural and mechanical integrity under process constraints, ensuring predictable therapeutic release, and establishing reliable process-structure-property relationships.




Figure 2. Conceptual framework of bioactive integration and stimuli-responsive therapeutic release in AM metallic orthopedic implants.

2. Functional integration strategies for AM metallic implants

AM offers unique advantages for integrating bioactive substances into metallic orthopedic implants. The layer-by-layer fabrication process allows for flexible control over the geometry, surface characteristics, internal cavities, and composition of implants, thereby providing versatile platforms for the incorporation of functional bioactive substances. Based on the integration mode, bioactive substances can be integrated into AM metallic implants through three main strategies: surface modification, bulk alloying, and structural reservoirs. This chapter summarizes the bioactive substance types, fabrication approaches, and biomedical applications associated with these strategies.

2.1. Types of bioactive substances

The integration of various bioactive substances aims to actively endow implants with the ability to combat postoperative complications and promote tissue regeneration, mainly focusing on two directions: antibacterial/anti-inflammatory effects and osteogenic/angiogenic promotion (See Table 2).

(i) Antibacterial/anti-inflammatory effects

Among postoperative complications, implant-associated infection remains one of the major causes of implantation failure and revision surgery. Accordingly, localized delivery of antibacterial agents has become a widely adopted strategy for constructing a biological defense barrier at the implant–tissue interface. Conventional antibiotics, including vancomycin (Van), gentamicin (Gen), and rifampicin, are still the most extensively used antibacterial agents in implant systems. Van, a glycopeptide antibiotic effective against Gram-positive bacteria, is frequently incorporated into implants to suppress *Staphylococcus aureus* infection. Gen, an aminoglycoside antibiotic composed of C1, C1a, C2, and C2a four major components together with a minor component C2b.⁶² Benefiting from its broad antibacterial spectrum and good thermal stability, Gen has become one of the most commonly used antibiotics in antimicrobial coatings. Rifampicin exhibits potent dose-dependent bactericidal activity against Gram-positive bacteria.⁶³ Mechanistically, this semisynthetic antibiotic selectively inhibits bacterial RNA synthesis by targeting the β subunit of RNA polymerase.^{64,65} More importantly, rifampicin demonstrates pronounced anti-biofilm capability and intracellular antibacterial activity, making it particularly important in the treatment of periprosthetic joint infection.⁶⁶

Besides conventional antibiotics, naturally derived antibacterial materials have attracted increasing interest owing to their improved biocompatibility and lower risk of inducing bacterial resistance. Chitosan (CS), a polycationic natural polymer obtained through partial or complete alkaline deacetylation of chitin derived from crustacean shells,⁶⁷ has been widely investigated in therapeutic delivery systems, antimicrobial coatings, tissue-engineering scaffolds, and wound dressings because of its biodegradability, low cytotoxicity, and broad-spectrum antimicrobial activity.⁶⁸ Its antibacterial effect is mainly associated with electrostatic interactions between positively charged polymer chains and negatively charged bacterial cell-wall components, which disrupt membrane integrity and induce leakage of intracellular substances.⁶⁹ In addition, low-molecular-weight CS can penetrate bacterial cell walls and interfere with intracellular DNA replication or transcription. CS can also chelate environmental metal ions and essential nutrients, thereby further inhibiting bacterial proliferation.⁷⁰

Antimicrobial peptides (AMPs), another important class of bioactive antibacterial agents, are widely present in innate immune systems and exhibit broad-spectrum antimicrobial activity together with potent anti-biofilm capability at relatively low concentrations.⁷¹ Compared with traditional antibiotics, AMPs show a substantially lower tendency to induce bacterial resistance.⁷² Their antibacterial activity is largely attributed to their cationic nature, which enables membrane disruption through electrostatic interactions with bacterial surfaces. In addition, AMPs can inhibit DNA, RNA, and protein synthesis while simultaneously regulating host immune responses.⁷³ Importantly, AMPs are capable of eliminating not only planktonic bacteria but also bacteria embedded within biofilms.⁷⁴

Inorganic antibacterial agents, including silver/silver nanoparticles (Ag/AgNPs), copper/copper oxide nanoparticles (Cu/CuONPs), and zinc/zinc oxide nanoparticles (Zn/ZnONPs), have also been extensively explored because of their long-term antibacterial stability.^{75,76} These metallic ions or nanoparticles exert bactericidal effects mainly by interacting with negatively charged bacterial membranes, thereby inducing membrane perforation and intracellular leakage. Some ions can additionally bind to bacterial proteins, enzymes, or DNA, leading to metabolic dysfunction and cell death.^{77,78} Furthermore, antibacterial metallic ions can be incorporated into coatings alongside osteogenic ions, such as Sr^{2+} ,⁷⁹ Zn^{2+} ,⁸⁰ thereby enabling the coatings to exhibit both antibacterial and osteogenic properties.

Beyond bacterial infection, excessive inflammatory responses can also compromise

osseointegration and long-term implant stability. Therefore, increasing attention has been directed toward incorporating immunomodulatory agents capable of regulating the local inflammatory microenvironment. Most anti-inflammatory strategies are based on promoting macrophage polarization from the pro-inflammatory M1 phenotype toward the pro-regenerative M2 phenotype. Representative agents include anti-tumor necrosis factor- α (TNF- α) therapeutics such as infliximab, adalimumab, and the fusion protein etanercept, as well as interleukin-4 (IL-4), luteolin, curcumin, and certain bioactive metallic ions. Through modulation of macrophage behavior, these agents can suppress the expression of pro-inflammatory cytokines, including interleukin-1 β (IL-1 β), interleukin-6 (IL-6), and TNF- α , thereby alleviating chronic inflammation and creating a more favorable microenvironment for tissue repair and regeneration.⁸¹

(ii) Osteogenic/angiogenic promotion

Effective bone defect repair not only requires strong osteoinductive stimulation but also depends on sufficient vascularization to supply nutrients and oxygen. To this end, various osteogenic and angiogenic agents have been widely applied in implant functionalization strategies. Among them, growth factors are considered some of the most potent bioactive regulators. Bone morphogenetic proteins (BMPs), particularly BMP-2 and BMP-7, can effectively promote the osteogenic differentiation of mesenchymal stem cells (MSCs) and stimulate new bone formation.^{82,83} In addition, transforming growth factor- β (TGF- β) has also been widely investigated because of its important roles in extracellular matrix remodeling.⁸⁴

Meanwhile, angiogenic growth factors such as vascular endothelial growth factor (VEGF), fibroblast growth factor-2 (FGF-2), and platelet-derived growth factor (PDGF) have been reported to play roles in either angiogenesis or osteogenesis, thereby contributing to vascularized tissue regeneration and bone formation.^{85,86} Notably, some of these factors may also influence both processes, highlighting the close interplay between vascularization and bone formation during tissue repair.

Besides growth factors, bioactive ions such as strontium ions and silicon ions, as key components of bioactive glass or doped coatings, can continuously stimulate osteoblast activity and promote bone mineralization during sustained release. In addition, small-molecule drugs such as dexamethasone (Dex), icariin (ICA), and zoledronic acid (ZOL) have also shown considerable potential in regulating the peri-implant microenvironment. Dex and ICA can promote osteogenic differentiation and vascularization through modulation of osteogenesis- and angiogenesis-related

signaling pathways. ZOL primarily suppresses osteoclast-mediated bone resorption and peri-implant osteolysis, thereby contributing to improved osseointegration and implant stability.

Collectively, the integration of antibacterial, immunomodulatory, osteogenic, and angiogenic agents enables metallic implants to actively modulate the peri-implant microenvironment, thereby improving infection control, immune regulation, vascularized bone regeneration, and ultimately long-term implant integration.

Table 2. Representative bioactive substances incorporated into metallic implants for infection control, immunomodulation, and vascularized bone regeneration.

Functional category	Representative substances	Main mechanisms	Biological functions	References
Antibiotics	Van, Gen, rifampicin	Inhibition of bacterial cell wall, protein, or RNA synthesis	Antibacterial therapy of implant-associated infection	62-66
Natural antibacterial polymers	CS	Electrostatic interaction with bacterial membranes; membrane disruption; interference with intracellular DNA replication/transcription; nutrient chelation	Broad-spectrum antibacterial activity and improved biocompatibility	67-69
Antimicrobial peptides	AMPs	Membrane disruption; inhibition of DNA/RNA/protein synthesis; immunomodulation	Antibacterial and anti-biofilm activity against planktonic and biofilm-embedded bacteria	71-74
Inorganic bioactive ions	Ag, Cu, Zn, Sr (released as ions)	Membrane disruption, ROS generation, intracellular leakage, and metabolic	Relatively long-lasting antibacterial activity; promotion of bone mineralization and bone	75-80

Functional category	Representative substances	Main mechanisms	Biological functions	References
		dysfunction (antibacterial); regulation of osteoblast activity and mineralization-related pathways (osteogenic)	regeneration	
Immunomodulatory agents	Infliximab, adalimumab, etanercept, IL-4, luteolin, curcumin, bioactive metallic ions	Regulation of macrophage polarization; suppression of inflammatory signaling	Reduction of excessive inflammatory responses and establishment of a pro-regenerative microenvironment	⁸¹
Osteogenic growth factors	BMP-2, BMP-7, TGF- β	Regulation of osteogenic differentiation and extracellular matrix remodeling	Promotion of MSC osteogenic differentiation and new bone formation	⁸²⁻⁸⁴
Angiogenic growth factors	VEGF, FGF-2, PDGF	Regulation of endothelial cell migration, proliferation, and neovascularization	Promotion of vascularized tissue regeneration	^{85,86}
Small-molecule bioactive drugs	Dex, ICA, ZOL	Modulation of osteogenesis-, angiogenesis-, and bone-remodeling-related signaling pathways	Promotion of bone regeneration, vascularization, and suppression of peri-implant osteolysis	⁸⁷⁻⁹¹

2.2. Surface modification strategies

Surface functionalization represents one of the most versatile post-fabrication approaches for endowing AM metallic implants with biological and therapeutic functions. By constructing bioactive interfaces on implant surfaces or within porous architectures, surface functionalization enables localized regulation of cell behavior, antibacterial activity, osseointegration, and therapeutic delivery while largely preserving the bulk structural properties of the substrate.

Depending on the formation mechanism and interfacial characteristics of the functional layer, current surface functionalization strategies can be broadly classified into four categories: solution deposited functional coatings, interfacial molecular functionalization, in situ electrochemical conversion coatings, and vapor deposited inorganic films (Fig. 3). Solution deposited functional coatings mainly serve as reservoirs for therapeutic agents and bioactive ions; interfacial molecular functionalization introduces biological signaling motifs at the molecular scale without markedly changing surface morphology; in situ conversion coatings generate substrate-derived oxide or ceramic layers with strong interfacial adhesion; and vapor deposited inorganic films provide dense, durable protection while enabling long-term biological functionality.




Figure 3. Classification of surface modification strategies for AM metallic implants, including deposited functional coatings, interface molecular functionalization, in situ electrochemical conversion coatings and vapor deposited inorganic functional films.

(i) Solution deposited functional coatings

Solution deposited functional coatings are among the most direct and widely used surface engineering strategies for enabling localized therapeutic functions in AM metallic implants. This method introduces an independently existing functional phase onto implant surfaces or within porous structures via dip coating, sol-gel reactions, or in situ hydrogel gelation.

Such coatings generally exhibit good biocompatibility and biodegradability, serving as reservoirs for drugs, growth factors, or bioactive ions, thereby providing active therapeutic effects in antibacterial action, osteogenesis, and angiogenesis. This solution-based strategy is applicable to virtually all metallic materials used in orthopedic implants, yet the design rationale differs between non-degradable and biodegradable substrates. For non-degradable metals, the coating serves primarily as a therapeutic reservoir to impart antibacterial, osteogenic, or anti-inflammatory functions onto an otherwise bioinert surface. Here, coating stability and sustained release are the main concerns. In the case of biodegradable metals, the coating can also regulate the degradation

kinetics and control the sudden release of metal ions. This dual function makes the coating design more complex. Depending on the coating composition, these systems can mainly be categorized into polymer/hydrogel coatings and bioactive ceramic coatings.

Organic polymer/hydrogel coatings: Polymer and hydrogel-based coatings represent a major category. Thermosensitive or ionically crosslinked hydrogels physically loaded onto implants are widely used. In this approach, drug- or ion-containing hydrogel precursor solutions are directly infused into the interconnected pores of AM porous metal scaffolds, where temperature-triggered phase transition or ion-mediated crosslinking induces in situ gel formation, enabling localized sustained release of bioactive substances. Bai *et al.*⁸⁷ mixed ZOL with a poloxamer 407 hydrogel precursor and infused the mixture into electron beam melted porous Ti6Al4V scaffolds, forming a ZOL/gTi composite system. Gelation at 37 °C immobilized the drug within the scaffold, enabling sustained ZOL release ($\approx 63\%$ cumulative release over 28 days). In vitro results showed enhanced osteogenic differentiation of human bone marrow mesenchymal stem cells (hBMSCs) and downregulation of osteoclast-related genes, while in an osteoporotic rabbit model the system significantly improved osseointegration and interfacial stability. Zhu *et al.*⁸⁸ loaded ICA into a thermosensitive CS hydrogel on EBM porous Ti6Al4V scaffolds (ICA-GC-Ti), achieving sustained ICA release for over 17 days and significantly enhancing in vivo osseointegration. Beyond single-factor delivery, multifunctional hydrogel systems can also coordinate osteogenesis and angiogenesis. Sheng *et al.*⁹² developed a strontium-functionalized alginate–mineralized collagen hydrogel integrated into porous titanium scaffolds (aTi-Sr). Sustained Sr^{2+} release ($\approx 88\%$ over 28 days), combined with mineralized collagen, upregulated osteogenic gene expression (alkaline phosphatase (ALP), bone morphogenetic protein-2 (BMP-2), runt-related transcription factor 2 (Runx2)) in hBMSCs and enhanced angiogenic activity of human umbilical vein endothelial cells (HUVECs) via PI3K/AKT/mTOR signaling, resulting in simultaneous osteogenic and angiogenic enhancement in a rabbit femoral defect model. Li *et al.*⁸⁹ further loaded ICA into a low-molecular-weight alginate/mineralized collagen composite hydrogel combined with AM porous Ti6Al4V scaffolds, forming AMCI/PTi dual-functional scaffolds. Coordinated hydrogel degradation and drug diffusion enabled sustained ICA release ($\approx 77\%$ over 28 days), promoting both osteogenic differentiation of bone marrow stem cells and angiogenesis of HUVECs, with significant bone regeneration in a rabbit radial defect model. Chu *et al.*⁹⁰ fabricated a GelMA/PAAm interpenetrating hydrogel on titanium alloy surfaces via UV-initiated

polymerization and loaded ZOL. Arginine-glycine-aspartic acid (RGD) motifs from GelMA promoted early adhesion and proliferation of hBMSCs, while ZOL was slowly released ($\approx 64.1\%$ over 21 days), synergistically promoting osteogenesis while inhibiting osteoclast activity. While the above examples focused on non-degradable Ti6Al4V, polymer coatings are equally important for biodegradable metals. Wang *et al.*⁹³ immersed alkali-treated, negatively charged AM Mg-1Zn-1Ca scaffolds into a pH 5 collagen solution. Through electrostatic adsorption and EDC/NHS crosslinking, a stable $\sim 25\ \mu\text{m}$ -thick coating was formed. Acting as a physical barrier, it precisely regulated the 24 h Mg^{2+} release concentration from 10.69 mmol/L to 5.23 mmol/L—falling within the optimal therapeutic window (2–10 mmol/L) for osteogenesis and angiogenesis. In vitro, the coating promoted HUVEC migration and tube formation and upregulated osteogenic gene expression in MC3T3-E1 cells.

Bioactive ceramic coating: Bioactive ceramic coatings, represented by hydroxyapatite (HA) and calcium phosphate (CaP), are widely used because of their compositional similarity to the inorganic phase of bone. In addition to their intrinsic osteoconductivity, porous or nanostructured ceramic coatings can also serve as carriers for functional ions, thereby combining structural bioactivity with sustained release capability.⁹⁴ Knaislová *et al.*⁹⁵ used a sol-gel dip-coating technique to fabricate Ag and HA-doped TiO_2 composite coatings on AM porous Ti6Al4V structures. The coating provided nearly 100% antibacterial activity against *E. coli*, while HA promoted apatite formation. Notably, gyroid porous structures exhibited approximately fivefold higher Ag^+ release than solid rods due to larger specific surface area, highlighting the amplifying effect of AM porous architectures on surface modification and release behavior. Tabia *et al.*⁹⁶ fabricated 316L stainless steel lattice structures by SLM and dip-coated them with a 58S bioglass suspension. A silica pre-layer was optionally applied to improve adhesion. After heat treatment, the coating formed a uniform layer on the porous struts. In simulated body fluid, the coating induced the formation of a homogeneous apatite layer within 7 days, confirming its bioactivity. Ye *et al.*⁹⁷ deposited a Sr-doped octacalciumphosphate/strontium hydrogen phosphate (Sr-OCP/SrHPO₄) nanocomposite coating on SLM-fabricated porous JDBM magnesium alloy scaffolds. Acting as a barrier-supply integrated system, the dense coating slowed Mg degradation and burst Mg^{2+} release while continuously supplying osteogenic Sr^{2+} , Ca^{2+} , and PO_4^{3-} ions, better matching degradation with new bone formation.

(ii) Interface molecular functionalization

Interfacial molecular functionalization refers to the presentation of bioactive motifs directly at the implant interface through molecular-scale modifications. Unlike macroscopic coatings, this approach preserves the original surface topography and bulk mechanical properties while enabling precise regulation of cell adhesion, differentiation, and immune responses. Moreover, since binding peptides can be selected for different metal substrates, this approach is applicable not only to titanium alloys but also to other clinically relevant alloys such as Co-Cr-Mo, provided that suitable anchoring strategies are available. Depending on the mode of molecule–surface interaction, two main strategies are commonly employed: non-covalent adsorption via material-binding peptides and covalent grafting via silane chemistry.

The non-covalent strategy uses material-binding peptides identified via phage display bind spontaneously to specific metal surfaces through electrostatic, hydrophobic, and van der Waals forces. These peptides can be fused with functional motifs and immobilized via a simple one-step immersion process. A representative example of this strategy was reported by Zhao *et al.*⁹⁸, who designed chimeric peptides comprising a titanium-binding peptide (minTBP-1) and osteogenic (W9) or angiogenic (PR1P) motifs. The minTBP-1 domain enabled rapid, specific immobilization on AM titanium surfaces within 5 min without any chemical coupling agent. The molecular coating promoted cell migration, tube formation, and upregulation of osteogenic and angiogenic markers via BMP-2/Smad and VEGF/Akt/Erk pathways. A rigid (GP)₄ linker further enhanced bioactivity by maintaining domain separation. In a rat calvarial defect model, the modified implants increased bone volume (BV/TV) and new bone formation at 12 weeks. Beyond titanium, this molecular functionalization paradigm can be extended to other metallic biomaterials by identifying substrate-specific binding motifs. Migita *et al.*⁹⁹ screened a 12-mer peptide (CCM-BP04) from a phage-display library that exhibits high binding affinity to Co-Cr-Mo (CCM) alloy, a material widely used in coronary stents and artificial joints. This peptide binds equally well to cast CCM and to CCM fabricated by SLM. By fusing CCM-BP04 with the cell-adhesive RGDS motif, the resulting fusion peptide was immobilized onto SLM CCM surfaces via a simple 30 min immersion, enhancing endothelial cell attachment under both serum containing and serum free conditions. To address postoperative infection without compromising osseointegration, Cui *et al.*¹⁰⁰ addressed this challenge by designing a novel fusion peptide (NFP) that integrates a minTBP-1, an antimicrobial peptide KR-12, and the cell-adhesive peptide GFOGER in a single molecular chain (See Fig. 4). A stable molecular layer was formed on AM titanium implants through a simple immersion

process. This one-step modification simultaneously conferred over 90 % antibacterial efficiency against *E. coli* and *S. aureus* and significantly enhanced osteogenic activity, which was associated with activation of focal adhesion and PI3K-Akt signaling pathways.

The covalent strategy relies on silane chemistry to form stable M–O–Si bonds between silane coupling agents (e.g., 3-aminopropyltriethoxysilane, APTES) and hydroxyl-rich metal oxide surfaces, introducing reactive groups for subsequent conjugation of bioactive molecules via crosslinkers such as EDC/NHS or maleimide-thiol chemistry. Covalent grafting offers superior long-term stability compared to physical adsorption. For instance, Lei *et al.*¹⁰¹ functionalized 3D-printed Ti6Al4V scaffolds by first immobilizing APTES to create an amino-rich interface, followed by covalent conjugation of E7 peptides and umbilical cord mesenchymal stem cell-derived exosomes, significantly enhancing osteoporotic bone repair and multi-stage osseointegration in vivo. Collectively, interfacial molecular functionalization offers a simple and multifunctional platform to improve the bioactivity of AM metallic implants.




Figure 4. Peptide-mediated bio-specific functionalization: (A) Schematic of the fabrication process for 3D Ti implants functionalized with the multifunctional fusion peptide; (B) Representative images of *E. coli* and *S. aureus* colonies on different groups of modified Ti substrates. (C) Antibacterial rate (%) against *E. coli* and *S. aureus* of different groups. Reprinted with permission from¹⁰⁰, Copyright (2025), Elsevier.

(iii) In situ electrochemical conversion coatings

Electrochemical surface modification involves applying an electric field in a controlled electrolyte environment to induce in situ electrochemical conversion reactions on metal substrates, leading to the growth of oxide ceramic layers or ordered nanostructures that are metallurgically bonded to the underlying matrix.¹⁰² This strategy is primarily applicable to valve metals and their alloys (e.g., Ti, Ta, Mg). When an anodic voltage is applied in an electrolyte, these metals inherently form a dense, high-resistance oxide film, which serves as the physical basis for subsequent micro-arc discharges or the self-organized growth of nanostructures. By tuning the electrolyte composition, electrical parameters, and treatment duration, one can not only generate micro/nano-scale porous topographies but also simultaneously incorporate bioactive elements (e.g., Ca, P, Si, Sr) into the growing layer, thereby achieving synergistic structural regulation and chemical biofunctionalization.¹⁰³ Among the representative techniques, micro-arc oxidation (MAO) and anodic oxidation stand out. Both yield functional layers that originate from substrate-derived conversion growth, thus exhibiting favorable interfacial adhesion and long-term stability. These advantages make them highly attractive for promoting osseointegration, regulating the degradation behavior of biodegradable metals, and serving as versatile platforms for subsequent functional loading.

MAO is typically conducted under voltages exceeding the dielectric breakdown threshold, generating localized micro-arc discharges and transient high-temperature, high-pressure conditions that oxidize the substrate and drive reactions with electrolyte species. The resulting coatings are typically rough, porous TiO₂-based ceramic layers enriched with bioactive elements. Sun *et al.*¹⁰⁴ combined MAO with hydrothermal treatment to fabricate a CaP bioactive coating with hierarchical micro/nano topography on AM Ti6Al4V interbody fusion cages, significantly enhancing hBMSC adhesion, proliferation, and osteogenic differentiation, as well as improving spinal fusion outcomes in vivo. Xiu *et al.*¹⁰⁵ directly applied MAO to AM porous Ti6Al4V scaffolds, producing a Ca–P-rich microporous TiO₂ layer that markedly improved bone ingrowth. Yang *et al.*¹⁰⁶ performed MAO on EBMed low-modulus Ti-24Nb-4Zr-8Sn porous scaffolds, forming a ceramic layer containing Nb₂O₅ and SnO₂. This treatment increased surface hydrophilicity and roughness while synergistically promoting osteogenic differentiation of hBMSCs and polarization of macrophages toward the anti-inflammatory M2 phenotype, resulting in favorable osseointegration both in vitro and in vivo. MAO can also generate bioactive coatings

with in vitro mineralization activity on AM Mg alloys. Yue *et al.*¹⁰⁷ performed MAO on SLM AZ91D Mg alloy at 350 V for 30 min. The $\text{Mg}_3(\text{PO}_4)_2$ phase was formed in situ by reaction of PO_4^{3-} with Mg^{2+} released from the substrate. After 21 days of immersion in SBF, FTIR spectra detected PO_4^{3-} , CO_3^{2-} , and OH^- groups, confirming the formation of an apatite-like layer on the coating surface, which is the direct evidence of its in vitro mineralization capability and potential osseointegration bioactivity.

Beyond osteogenic regulation, MAO-derived oxide layers can also serve as multifunctional platforms for incorporating antibacterial agents. By embedding therapeutic ions or nanoparticles into the oxide matrix, these coatings can achieve sustained antibacterial activity while maintaining favorable osteocompatibility. Fazel *et al.*¹⁰⁸ combined MAO with hydrothermal treatment to construct AgNP- and HA-containing multifunctional coatings on porous SLM Ti6Al4V scaffolds, enabling sustained Ag^+ release for up to 28 days and effective inhibition of *Staphylococcus aureus* biofilm formation while simultaneously enhancing osteogenic activity. Similarly, van Hengel *et al.*¹⁰⁹ incorporated AgNPs into MAO layers on selective laser melted porous titanium implants using a Ca/P-based electrolyte. Compared with geometrically comparable solid implants, the interconnected porous architecture released approximately fourfold higher amounts of Ag^+ and exhibited enhanced antibacterial efficacy without detectable cytotoxicity. Interestingly, HA formation was observed only on the porous implants after MAO treatment, further suggesting that AM-enabled porous architectures can synergistically amplify the biological functionality of electrochemically generated coatings.

Anodic oxidation is another representative electrochemical conversion strategy widely applied to titanium and its alloys.¹¹⁰ Through a self-organized growth mechanism, anodization can generate highly ordered titania nanotube (TNT) arrays whose diameter, length, and wall thickness can be tuned by adjusting the applied voltage, electrolyte composition, and oxidation duration. This nanotubular architecture substantially increases the specific surface area and provides nanoscale reservoirs for drugs, proteins, or bioactive ions, while the nanoscale topography itself can also regulate cell adhesion and differentiation. Zhang *et al.*¹¹¹ fabricated Ta_2O_5 nanotube arrays on SLM porous tantalum scaffolds via electrochemical anodization. The nanotubular surface transformed the substrate from hydrophobic to superhydrophilic and enhanced protein adsorption. In vitro results demonstrated that the modified scaffolds promoted adhesion, spreading, and osteogenic gene expression (Osterix, Runx2, COL-I) of MC3T3-E1 preosteoblasts. In a rabbit

femoral implantation model, more new bone ingrowth and collagen fiber formation were observed in the modified group as early as 2 weeks post-implantation, confirming that this hierarchical nanostructure effectively promotes early-stage osseointegration. Zhao *et al.*¹¹² further constructed ordered TiO₂ nanotube arrays on selective laser melted Ti6Al4V scaffolds using a two-step anodization process, followed by loading mesoporous bioactive glass. This composite structure enabled sustained release of Ca²⁺ and Si⁴⁺ ions, improving hydrophilicity and cytocompatibility, and providing a stable supply of bioactive ions for long-term bone regeneration.

(iv) Vapor deposition inorganic functional films

Vapor deposition techniques, including physical vapor deposition (PVD) and chemical vapor deposition (CVD), enable the formation of dense inorganic functional films with thicknesses ranging from nanometers to micrometers on metallic implants. In contrast to degradable drug-loading coatings, these films are primarily designed to provide durable mechanical and chemical protection, thereby improving wear and corrosion resistance while limiting unwanted ion release. When doped with Ag, Cu, or other functional elements, they can also impart long-lasting antibacterial or osteogenic activity. Because of their dense interfacial architecture, vapor deposited films are particularly valuable for load-bearing and long-term implantation scenarios, although conformal coverage in deep porous structures may still be limited by line-of-sight deposition characteristics. Vapor deposited inorganic films are applicable to metals with high melting points. These techniques require elevated temperatures (typically >300 °C) and high vacuum, making them unsuitable for low melting point metals which may melt, oxidize, or degrade during deposition.

Ran *et al.*¹¹³ deposited a tantalum (Ta) coating onto porous SLM-fabricated Ti6Al4V scaffolds via CVD. The coating not only suppressed the release of potentially toxic vanadium ions from the substrate but also significantly promoted stem cell osteogenic differentiation and in vivo osseointegration. Guo *et al.*¹¹⁴ applied arc ion plating to deposit TiCu/TiCuN multilayer coatings on porous SLM Ti6Al4V scaffolds. The release of Cu²⁺ activated the stromal cell-derived factor-1 α (SDF-1 α)/chemokine receptor type 4 (CXCR4) axis and related signaling pathways, effectively enhancing BMSC recruitment, adhesion, and osteogenic differentiation. Hu *et al.*¹¹⁵ employed filtered cathodic vacuum arc (FCVA) to deposit Ag-doped diamond-like carbon (Ag-DLC) coatings on SLM Ti6Al4V joint implants. DLC coatings are known for their extremely high hardness, low friction coefficient, and chemical inertness. With Ag incorporation, the coating

maintained desirable wear resistance (friction coefficient reduced by ~16.7%) and strong interfacial adhesion (increased by ~55%), while also providing durable, broad-spectrum antibacterial properties and good cytocompatibility. This highlights the advantage of vapor deposition techniques in integrating mechanical protection with biological functionality.

Overall, different functionalization strategies possess distinct pathways for functional implementation and application scenarios, collectively promoting AM metallic implants from passive structural replacements toward active therapeutic platforms (See Table 3). Solution deposited functional coatings offer the greatest flexibility in the integrating and controllable release of drugs and bioactive factors, making them suitable for constructing temporally regulated therapeutic microenvironments; however, their long-term interfacial stability still requires further improvement. Interface molecular functionalization, by contrast, relies on precise regulation at the molecular scale and can modulate cell behavior and immune responses without altering the macroscopic structure, yet the persistence of its function is limited by the availability of surface binding sites and the stability of functional molecules. In situ electrochemical conversion coatings combine morphological regulation with chemical activation, and since the functional layer originates from in situ transformation of the substrate, they exhibit strong bonding strength and long-term stability, showing notable advantages in promoting osseointegration and regulating the degradation of biodegradable metals. Vapor deposited inorganic functional films mainly focus on providing long-lasting mechanical and chemical protection by forming dense interfacial layers that enhance wear and corrosion resistance, and they can also introduce long-term stable antibacterial or osteogenic elements. While a single strategy is insufficient to meet complex clinical demands, multi-technology coupling is becoming an important development direction. By integrating structurally stable interfaces with release-capable functional layers or molecular functionalization approaches, synergistic optimization among mechanical performance, biological activity, and therapeutic function can be achieved.

Table 3. Comparison of surface modification strategies for the integration of bioactive substances on AM metallic implants.

Surface strategy	Applicable metallic substrates	Carrier matrix for Active Substances	Integrated active substances	Core implementation mechanism
Solution deposited functional coatings	Virtually all metallic frameworks (Ti6Al4V, 316L stainless steel, and biodegradable Mg alloys).	Polymer/Hydrogel: Poloxamer 407, CS, alginate, GelMA, and collagen. Bioactive ceramics: HA, CaP, and 58S bioglass.	Exogenous therapeutic drugs (ZOL, ICA), growth factors, and bioactive ions (Sr^{2+} , Ag^{+}).	Introduces an independent physical functional phase into porous architectures via dip coating, sol-gel, or in situ gelation, serving as a versatile reservoir for bioactive substances release.
Interface molecular functionalization	Primarily applied to (Ti) and extendable to other clinical alloys via substrate-specific screening.	No macroscopic physical film: A molecular-level interface composed of self-assembled monolayer/few-layer material-binding peptides (e.g., minTBP-1, CCM BP04, NFP).	Bio-specific functional motifs (osteogenic W9, angiogenic PR1P, cell-adhesive RGD/RGDS, and antimicrobial KR-12).	Employs material-binding peptides (via phage display) for non-covalent adsorption, or silane-based covalent grafting, to engineer the interface at the molecular scale while preserving the original topography.
In situ electrochemical conversion coatings	Primarily used for valve metals and their alloys, such as Ti6Al4V, low-modulus Ti-24Nb-4Zr-8Sn, Ta, and biodegradable Mg alloys.	Substrate-derived, in situ grown oxide ceramic layers (e.g., TiO_2 , Ta_2O_5 , $\text{Mg}_3(\text{PO}_4)_2$) or highly ordered self-organized nanotube arrays.	Electrolyte-derived doping elements (Ca, P, Si, Sr) and post-loaded functional nanostructures (e.g., AgNPs, mesoporous bioglass).	Applies a controlled electric field to trigger micro-arc discharges or self-organized anodization, yielding functional conversion layers with exceptionally strong metallurgical bonding while coupling topographic and chemical modifications.

Surface strategy	Applicable metallic substrates	Carrier matrix for Active Substances	Integrated active substances	Core implementation mechanism
Vapor deposition inorganic functional films	High-melting-point alloys; strictly.	Nano to micro scale dense inorganic protective films fabricated via PVD or CVD (e.g., pure Ta coatings, TiCu/TiCuN multilayers, and carbon films).	Long-lasting therapeutic metallic elements (e.g., Cu, Ag) incorporated directly into the film lattice.	Deposits a highly dense, high-hardness barrier layer in a vacuum or vapor phase, prioritizing wear resistance and corrosion protection while physically suppressing the hazardous release of substrate metal ions.

2.3. Bulk alloying strategies

Bulk alloying represents a source-level strategy for constructing functional metallic implants by directly integrating bioactive elements into the metallic matrix during alloy preparation. In AM, this is typically achieved through pre-alloyed powders or in situ mixing of elemental powders prior to processing. Compared with surface modification strategies, bulk alloying enables metallurgical incorporation of therapeutic elements within the host matrix, thereby providing intrinsic bioactivity and improved long-term stability. Importantly, the biological mechanisms of bulk-alloyed systems strongly depend on material stability. In biodegradable alloys, therapeutic effects are closely coupled with matrix degradation, ion release, and microstructural evolution. By contrast, in chemically stable systems such as Ti–Ta and Ti–Nb alloys, biological responses are more frequently mediated by surface oxide chemistry, wettability, and interfacial immune regulation rather than extensive ionic release. Owing to the absence of coating/substrate interfaces, bulk alloying can also avoid delamination and interfacial instability commonly observed in surface-coated systems, making it particularly attractive for long-term orthopedic applications requiring durable osseointegration, immune regulation, and antibacterial functionality.

(i) Stable therapeutic alloy systems for osteoimmunomodulation

Among stable therapeutic alloy systems, Ta and Nb have received extensive attention because of their favorable biocompatibility and immunomodulatory potential. Ta is well known for its

osteoconductivity, corrosion resistance, and chemical stability. Alloying Ta with Ti aims to combine the favorable processability of Ti with the biological affinity of Ta. Brodie *et al.*¹¹⁶ fabricated Ti25Ta and Ti65Ta alloys via SLM using mixed elemental powders. Compared with conventional Ti6Al4V, both alloys enhanced early osteogenic differentiation and mineralization of hBMSCs, indicating that osteogenic functionality can be introduced through compositional regulation alone. To further improve compositional uniformity, Li *et al.*¹¹⁷ developed pre-alloyed TaTi spherical powders and fabricated a series of TaTi alloys via SLM. The resulting Ta55 alloy exhibited a favorable balance between mechanical strength and elastic modulus. More importantly, the Ta₂O₅/TiO₂ mixed oxide layer formed on the alloy surface effectively suppressed pro-inflammatory signaling and promoted macrophage polarization toward the reparative M2 phenotype, thereby establishing an immune microenvironment favorable for bone regeneration.

Beyond Ta-containing systems, Nb alloying has emerged as another effective route for osteoimmunomodulation. Liang *et al.*¹¹⁸ fabricated porous Ti–Nb scaffolds through in situ alloying of Ti and Nb powders during SLM processing. The incorporation of Nb altered the composition of the surface oxide layer by forming Nb₂O₅ and simultaneously improved surface hydrophilicity. More importantly, Nb₂O₅-rich surfaces effectively promoted macrophage polarization toward the anti-inflammatory M2 phenotype, leading to increased expression of osteogenic and angiogenic factors such as BMP-2 and VEGF. In vivo, Ti-25Nb scaffolds generated substantially greater bone formation than pure Ti scaffolds in a rabbit bone defect model. These findings collectively suggest that stable bulk-alloyed systems can regulate osseointegration not only through direct osteogenic stimulation, but also through modulation of the peri-implant immune microenvironment.

(ii) Biodegradation-coupled therapeutic alloy systems

For biodegradable metallic systems, therapeutic functionality is closely associated with degradation behavior and ion-release dynamics. Among these systems, Zn–Mg alloys have attracted increasing attention because Mg incorporation can simultaneously regulate mechanical performance, corrosion behavior, and biological activity. Liu *et al.*¹¹⁹ and Qin *et al.*¹²⁰ demonstrated that SLM-fabricated Zn–Mg alloys, including Zn-0.4Mg and Zn-1Mg, exhibited significantly improved overall performance after Mg addition. Mechanistically, Mg incorporation modifies microstructure, phase constitution, corrosion-product formation, and local electrochemical behavior, thereby affecting both degradation kinetics and mechanical stability.

Concurrently, Mg^{2+} released during degradation can serve as an osteogenic cue to promote osteoblast proliferation and differentiation. Qin *et al.*¹²⁰ further reported that porous Zn-1Mg scaffolds maintained compressive properties comparable to cancellous bone while achieving a favorable balance between degradation rate and osteogenic activity. These studies highlight a defining feature of biodegradable bulk alloying strategies: biological functionality is dynamically coupled with degradation-induced microstructural and chemical evolution.

(iii) Alloy-enabled anti-infective functionality

Incorporating antibacterial elements directly into metallic matrices represents an effective strategy for constructing long-lasting anti-infective implants. Among various antibacterial alloying elements, Cu has attracted particular attention because of its combined antibacterial, anti-inflammatory, and pro-angiogenic activities. Xu *et al.*¹²¹ fabricated Ti6Al4V-Cu alloys via SLM for osteoporotic bone repair applications. The alloy exhibited homogeneous Cu distribution and sustained low-concentration Cu^{2+} release. The released Cu^{2+} inhibited osteoclast differentiation, suppressed pro-inflammatory M1 macrophage activation, and promoted extracellular matrix synthesis by osteoblasts, thereby simultaneously alleviating inflammation and enhancing osteogenesis under osteoporotic conditions.

In dental restoration applications, Xu *et al.*¹²² further alloyed 6 wt.% Cu into Ti6Al4V to develop an antibacterial crown material. The Ti6Al4V-6Cu alloy maintained favorable mechanical properties and corrosion resistance while exhibiting pronounced antibacterial activity against *Streptococcus mutans*. In addition to inhibiting biofilm formation, the alloy also downregulated bacterial virulence-associated gene expression without compromising cytocompatibility. These findings demonstrate that alloy-enabled antibacterial functionality can provide durable anti-infective capability while preserving the structural integrity of metallic implants.

(iv) ML-driven alloy design and manufacturing

Although bulk alloying strategies offer advantages in long-term functional stability, their primary challenge lies in complex trade-offs under multi-objective constraints: the type and concentration of functional elements must simultaneously satisfy cytotoxicity thresholds, biological activity requirements, mechanical support capability, corrosion and degradation rates, and AM processability. Traditional experience-based trial-and-error alloy development approaches are inefficient for optimization in high-dimensional composition and processing spaces. Consequently, machine learning (ML) is emerging as an important tool for compositional design and process

alloys. In the future, incorporating degradation kinetics, ion release behavior, and cellular responses into unified multiscale models may enable fully intelligent design workflows spanning alloy composition design, AM process optimization, and prediction of in vivo functional performance, thereby accelerating the development of actively therapeutic metallic implants.

Overall, bulk alloying introduces bioactive elements directly at the material scale, providing implants with long-term functionality without the need for additional carriers. This strategy avoids interfacial instability issues such as coating delamination; however, it also faces intrinsic trade-offs because the biological windows of different elements may overlap or conflict, and the desired therapeutic effect must be balanced against mechanical integrity, corrosion behavior, and processability

2.4. Structural integration strategies

Structurally integrated therapeutic reservoirs represent a unique strategy enabled by the geometric freedom of AM, in which internal cavities, microchannels, or functionally partitioned architectures are directly incorporated into implants to achieve localized drug storage and release. Unlike surface-based loading approaches, therapeutic functionality in this strategy is embedded within the implant architecture itself, thereby enabling spatial separation between load-bearing regions and drug-delivery regions while preserving the overall mechanical integrity of the implant.

Within dense or partially dense implants, closed or semi-closed cavities (reservoirs) and micrometer-scale channels connecting to the surface can be directly printed to create built-in storage spaces. Šalandová *et al.*¹²⁹ used SLM to fabricate interconnected subsurface reservoirs and surface microchannels inside Ti6Al4V implants (See Fig. 6). After loading the reservoirs with a hydrogel containing AMPs, the openings were sealed using a poly(lactic-co-glycolic acid) (PLGA) film. An exogenous alternating magnetic field was then applied to induce eddy current heating within the implant, causing thermal phase transition and rupture of the PLGA film, thereby enabling remote, on-demand drug release. Following AMF triggering, the system achieved rapid and efficient release, with 99% release within 20 hours. Moreover, systematic cell experiments confirmed that the loaded AMPs exhibited good biocompatibility at their minimum bactericidal concentration and did not significantly interfere with macrophage polarization or early osteogenic marker expression in pre-osteoblasts. Karavasili *et al.*¹³⁰ further demonstrated that structural parameters can directly regulate release kinetics. They designed and fabricated hollow reservoirs with different surface pore patterns in Ti6Al4V pedicle screws. Systematic comparisons confirmed

that pore size, number, and spatial distribution are key variables for programming drug release behavior. A lattice-like helical pore design with larger pore size exhibited a higher initial burst release due to its greater exposed surface area, whereas a central channel design with smaller rhombic pores was more favorable for sustained long-term release. These studies collectively demonstrate that AM-enabled internal architectures are not merely passive structural features, but can function as programmable therapeutic reservoirs whose release behavior is governed by geometrical parameters such as pore topology, channel connectivity, and diffusion path length.

Structurally integrated strategies highlight the unique capability of AM to integrate therapeutic functionality directly into implant architectures. Compared with conventional surface loading approaches, these systems enable higher drug-loading capacity, programmable release behavior, and spatial separation between mechanical support and therapeutic delivery. Nevertheless, their release profiles are still largely predetermined by structural geometry and diffusion pathways established during fabrication. Further development therefore requires more adaptive release systems capable of responding to the dynamically evolving biological microenvironment.




Figure 6. Structural integration strategy: (A) Real-scale implant and the preparation process of the hydrogel-dye loaded samples with a PLGA film; (B) Morphology and structural optimization of the 3D-printed samples: (i) macroscopic image and cross-section; (ii) trend of pore formation (red arrows) with decreasing hatching distance from 150 μm to 90 μm ; (iii) cross-sectional view of a sample printed with the final parameters, showing the integrated reservoir and delivery conduit; (C) Microstructural and topographical characterization of the reservoir and conduit (final parameters): (i, ii) images obtained by scanning electron microscopy (SEM) and optical profilometry, respectively; (iii) depth line profile of the reservoir measured by the profilometer. Reprinted with permission from ¹²⁹, Copyright (2024), John Wiley & Sons.

Overall, current strategies for integrating bioactive substances into AM metallic implants can be broadly categorized into surface modification, bulk alloying, and structurally integrated strategies (See Table 4). Surface modification primarily regulates interfacial bioactivity and localized therapeutic delivery through coatings or molecular functionalization. Bulk alloying introduces intrinsic and long-term functionality directly at the material level through metallurgical incorporation of therapeutic elements. Structurally integrated reservoirs exploit the geometric freedom of AM to achieve spatially programmable drug storage and release.

Table 4. Comparison of therapeutic integration strategies in AM metallic implants

Strategy	Functional mechanism	Advantages	Limitations
Surface modification strategies	Functionalization through coatings, material-binding peptides, in situ electrochemical conversion layers, or vapor deposited films on implant surfaces	High versatility; convenient post-processing; tunable release behavior; suitable for multifunctional integration	Limited long-term interfacial stability; possible coating delamination or burst release
Bulk alloying strategies	Intrinsic incorporation of bioactive elements into the metallic matrix through metallurgical alloying	Long-term stable functionality; uniform elemental distribution; avoids coating-related instability	Trade-offs among cytocompatibility, mechanics, and processability; limited flexibility after fabrication
Structural integration strategies	Drug storage and release enabled by AM-designed internal cavities, channels, or partitioned architectures	High loading capacity; programmable release kinetics; spatial separation of mechanical and therapeutic functions	Fabrication complexity; sealing reliability; risk of channel blockage or incomplete release

Collectively, current bioactive integration strategies have enabled AM metallic implants to evolve from passive structural substitutes toward localized therapeutic platforms. However, most existing systems still rely on pre-programmed therapeutic release profiles determined during fabrication, where the timing, dosage, and duration of release are largely fixed in advance. Such static therapeutic paradigms remain insufficient for addressing the dynamically evolving peri-implant microenvironment, in which infection progression, inflammatory fluctuations, oxidative stress, and tissue regeneration continuously change over time. Therefore, the next developmental stage of therapeutic metallic implants is shifting from integrated bioactivity toward adaptive therapeutic regulation, where implants are expected not only to carry therapeutic agents, but also

to actively sense pathological changes and dynamically modulate therapeutic responses in real time.

3. Stimuli-responsive release strategies for bioactive substances of metallic implants

Conventional sustained release systems generally rely on drug diffusion, concentration gradients, or the gradual degradation of carrier materials to achieve prolonged delivery of bioactive substances. Such strategies have significantly advanced local therapy in orthopedic implants. However, their release behaviors are typically predetermined at the time of implantation, making it difficult to dynamically adapt to the continuously changing pathological microenvironment in vivo. In comparison, controlled release places greater emphasis on the regulation of the release process itself, including the tunability of release rate, release timing, dosage, and responsiveness. However, the microenvironment surrounding implants is highly dynamic. Pathological events such as bacterial infection, aggravated inflammation, and oxidative stress imbalance are often unpredictable, and conventional pre-programmed sustained-release strategies may therefore be insufficient to meet therapeutic demands at different stages.

To overcome this limitation, research has increasingly shifted toward the development of stimuli-responsive implants, which use pathological microenvironmental signals in vivo or exogenous physical fields as triggers to initiate, accelerate, or regulate the release of therapeutic agents on demand. Within this framework, endogenous or exogenous stimuli do not act as therapeutic agents themselves but serve as regulatory input signals to control the timing and dosage of active substance delivery. According to the source of triggering signals, these approaches can be further categorized into endogenous stimuli-responsive strategies and exogenous stimuli-responsive strategies, each with characteristics in triggering mechanisms, controllability, and clinical implementation challenges.

3.1 Endogenous stimuli-responsive release strategies

The core of this strategy lies in exploiting the inherent biochemical differences between diseased sites and normal physiological environments as triggers, thereby achieving targeted and spontaneous therapeutic activation. By mimicking the body's natural feedback regulation mechanisms, this responsive mode avoids the systemic side effects of continuous drug release and the complexity of external intervention, enhancing therapeutic safety and specificity.

Endogenous responsive systems utilize biochemical changes in the local pathological microenvironment as intrinsic triggering signals for therapeutic activation. These triggers typically include pH variations, elevated expression of specific enzymes, abnormal ROS levels, and changes in inflammation-related molecules (See Fig. 7). Because their activation depends on disease-associated signals, such systems possess a certain degree of biological specificity and autonomous regulation without the need for external intervention.




Figure 7. Schematic of the endogenous stimuli-responsive release strategies including pH, enzyme and ROS.

3.1.1. pH-responsive release strategies

Pathological processes such as infection, inflammation, and tumors often lead to acidification of the peri-implant microenvironment, providing a specific signal for stimuli-responsive activation. pH-responsive systems incorporate chemical bonds or polymers sensitive to proton concentration, enabling degradation or conformational changes of drug carriers under acidic conditions, thereby accelerating the release of therapeutic molecules. Their core advantage lies in distinguishing diseased tissues from healthy ones, thus minimizing off-target toxicity to normal cells.

In response to different clinical challenges, pH responsiveness has demonstrated diverse design strategies. For integrated bone tumor therapy, Fan *et al.*¹³¹ developed a composite material (TS@PAP) based on an AM titanium scaffold. This system used acid-labile acetal bonds to link a paclitaxel prodrug, enabling rapid and burst drug release (85.33% within 72 h) in a simulated tumor acidic microenvironment (pH 6.5), while maintaining slow release under physiological pH (~11.28%). This design achieved highly selective killing of residual tumor cells while preserving a therapeutic window for subsequent bone regeneration.

In the prevention of implant-related infections, Pereira *et al.*¹³² constructed a pH-sensitive thin film based on PMAA on titanium implant surfaces. Protonation of carboxyl groups in acidic environments caused polymer chain contraction, thereby regulating tetracycline release from the underlying drug-loaded multilayers. This system not only effectively inhibited various biofilms but also promoted the activity of cells involved in soft tissue repair, demonstrating the dual potential of smart surface coatings in infection control and tissue integration. Furthermore, Zhou *et al.*¹³³ utilized the conformational transition of SF from α -helix to β -sheet under acidic conditions, which transformed originally dense coatings into looser structures, thereby accelerating the release of loaded Ag^+ and AMPs and enabling an infection-triggered intelligent antibacterial “switch”. Zhang *et al.*¹³⁴ designed a pH-responsive adaptive coating based on a quaternary ammonium–carboxyl copolymer (PQA-3). In this coating, antibacterial quaternary ammonium centers were electrostatically shielded by negatively charged carboxyl groups under physiological pH, exhibiting good biocompatibility and promoting osteogenesis. Under acidic infection conditions, the quaternary ammonium centers became exposed, disrupting bacterial membranes via electrostatic interactions and enabling on-demand antibacterial activation.

With the development of AM, pH-responsive mechanisms have been deeply integrated with the macroscopic structural design of implants, enabling more complex therapeutic logic. Zeng *et al.*¹³⁵ fabricated titanium alloy implants with integrated funnel-shaped drug reservoirs using SLM. By combining osmotic pressure differences induced by pH reduction with protonation-driven swelling of drug-loaded gelatin microspheres, the system achieved adaptive feedback between infection severity and drug release rate. Similarly, Baek *et al.*⁹¹ developed a pH-responsive hydrogel based on an injectable ABA triblock copolyether and loaded it into drug-storage cavities of SLM-printed titanium implants. This hydrogel underwent a sol–gel transition in acidic

inflammatory environments, enabling controlled release of Dex and achieving on-demand local anti-inflammatory therapeutic delivery.

For diseases such as osteoporosis accompanied by complex metabolic abnormalities, Li *et al.*¹³⁶ integrated a rapamycin-loaded polyvinyl alcohol-carboxymethyl CS-agarose/silver nanowires (PVA-NCCES-AG/Ag NWs) hydrogel onto the surface of AM porous titanium alloy implants, constructing a hydrogel coating responsive to both pH and competitive molecules. This system relied on a dynamic boronate ester covalent network, undergoing reversible gel–sol transitions in acidic and high-metabolite microenvironments, thereby enabling controlled rapamycin release to activate autophagy pathways in osteoporosis-derived stem cells and promote osteogenic differentiation. Meanwhile, Ag NWs provided baseline long-term antibacterial activity, demonstrating synergistic responsiveness and therapeutic effects toward multidimensional pathological signals.

3.1.2. Enzyme-responsive release strategies

Enzyme-responsive systems use specific enzymes that are overexpressed during disease progression or healing processes as biological triggers. By designing peptide or polymer chains that can be specifically cleaved by these enzymes, localized and temporally controlled drug release can be achieved. This strategy typically exhibits high biological specificity, with therapeutic activation closely linked to the pathological process itself.

Among various endogenous stimuli-responsive strategies, hyaluronic acid has become an ideal material for constructing enzyme-triggered release platforms due to its unique biological properties. First, hyaluronic acid is a natural component of the extracellular matrix, exhibiting favorable biocompatibility and biodegradability. Second, its strong hydrophilicity and negative charge enable the formation of hydration layers and electrostatic repulsion, providing broad-spectrum anti-bacterial adhesion capability. Hyaluronic acid can be specifically degraded by hyaluronidase (HAase) secreted by various pathogenic bacteria, such as *Staphylococcus aureus*. When infection occurs at the implant site, bacterial enzymes rapidly degrade the hyaluronic acid matrix, enabling rapid release of therapeutic agents.

Sutrisno *et al.*¹³⁷ constructed a HAase-sensitive chitosan/sodium hyaluronate–lauric acid (Chi/SL) multilayer film on the surface of titanium nanotubes loaded with the osteogenic factor BMP-2. When early infection occurred, HAase secreted by pathogenic bacteria degraded the hyaluronic acid matrix, simultaneously releasing the embedded natural antibacterial agent lauric

acid (LA, which functions by disrupting bacterial membranes and inhibiting virulence factor expression) and BMP-2. This strategy enabled early antibacterial action while initiating osseointegration without relying on traditional antibiotics, effectively interrupting the vicious cycle in which infection and bone healing inhibit each other.

Similarly, Yuan *et al.*¹³⁸ assembled multilayer films of catechol-functionalized hyaluronic acid and CS on vancomycin-loaded titanium dioxide nanotube arrays. This coating also responded to HAase secreted by bacteria, triggering intelligent release of Van, achieving an in vitro antibacterial rate exceeding 86%. In addition, catechol groups upregulated integrin gene expression, enhancing osteoblast adhesion and osseointegration. Furthermore, Yu *et al.*¹³⁹ combined enzyme responsiveness with angiogenic regulation by constructing HA–Gen multilayer films on DFO-loaded titanium nanotubes. HAase triggering enabled the simultaneous release of Gen and DFO, thereby synergistically suppressing infection and promoting the formation of a bone-repair microenvironment.

Such enzyme-responsive systems establish a closed-loop therapeutic logic from infection sensing to drug release and subsequent healing promotion. By avoiding systemic toxicity and antibiotic overuse, they effectively interrupt the vicious cycle between infection and impaired bone healing, providing a design paradigm for multifunctional integration in implants.

3.1.3. ROS -responsive release strategies

Pathological conditions such as chronic inflammation, diabetes, and osteoporosis are often accompanied by abnormally elevated local ROS levels. ROS-responsive systems incorporate materials containing ROS-sensitive chemical bonds, such as thioketal or selenium-based linkages, which undergo bond cleavage upon exposure to high ROS levels, thereby releasing loaded therapeutic agents. This strategy not only intervenes in the primary disease but also actively alleviates the negative effects of excessive oxidative stress on surrounding tissue repair.

Chen *et al.*¹⁴⁰ exploited the fine regulatory potential of ROS-responsive systems for treating comorbid pathological conditions and developed a functional coating (Ti/DNFzn/PDA-Nar) for titanium implants in osteoporotic environments. When ROS levels increased due to osteoporosis-associated inflammation at the implantation site, thioketal bonds in the coating cleaved, sequentially releasing Nar and DNFzn. Nar promoted angiogenesis by activating the eNOS/NO pathway, while DNFzn specifically degraded mRNA of the inflammation-related gene STING that was overexpressed intracellularly. This dual synergistic mechanism aimed to redirect disordered

angiogenesis in pathological conditions toward H-type vessel formation that supports osteogenesis, thereby improving the osseointegration microenvironment under osteoporotic conditions at the gene regulation level.

3.2 Exogenous stimuli-responsive release strategies

In addition to endogenous pathological signals, externally applied physical fields provide important means for achieving spatiotemporally precise control over the release of therapeutic agents. Unlike microenvironment-responsive systems that rely on disease-induced biochemical changes, exogenous stimuli can be applied on demand according to clinical needs, with flexible adjustment of intensity and duration. This section focuses on exogenous physical stimuli used to regulate the release behavior of preloaded therapeutic agents. These strategies convert externally supplied energy into physical or chemical changes within the carrier materials (such as localized heating, structural transitions, or enhanced molecular diffusion), thereby enabling controllable, noninvasive, and repeatable therapeutic delivery regulation. Representative exogenous triggers include light irradiation, magnetic fields, and electrical stimulation, each of which enables remote control over therapeutic release through distinct mechanisms (See Fig. 8).




Figure 8. Schematic of the exogenous stimuli-responsive release strategies including light, magnetism and electricity.

(i) Light-responsive release strategy

Light irradiation, with precisely controllable wavelength, intensity, and duration, has been widely applied in implant-related therapeutic strategies. In therapeutic delivery platforms for implants, light is increasingly used as a remote regulatory signal to modulate therapeutic release via photothermal conversion or photoresponsive structural changes. Near-infrared (NIR) light is particularly important due to its strong tissue penetration capability. Photothermal materials integrated into coatings or carrier matrices can convert NIR irradiation into localized heating, thereby inducing polymer softening, structural relaxation, or enhanced molecular diffusion to promote the release of preloaded active agents.^{141,142}

In early studies, the photothermal effect was used for direct antibacterial treatment on implant surfaces, laying the foundation for employing light as a remote-control tool. Wang *et al.*¹⁴³ constructed a nano-TiO₂ coating on SLM printed Ti6Al4V implants, successfully extending its photoresponsive activity to the 808 nm NIR region, thereby reducing potential photodamage to biological tissues. Under NIR irradiation at 0.8 W/cm², the coating temperature rose to 46.9 ± 0.32°C within 15 minutes. Through the synergistic effects of photothermal therapy (PTT) and physical nanostructure puncture, antibacterial rates against *Staphylococcus aureus* and *Escherichia coli* both exceeded 90% (See Fig. 9).




Figure 9. Light-responsive strategy: of Nano-TiO₂ coating. (A) Temperature change in 1 mL PBS under 808 nm NIR light irradiation (0.8 W/cm²). (B) Temperature variation during on/off illumination cycles. (C) Infrared thermal images of the sample. (D) Bacterial colonies of *E. coli* and *S. aureus* with or without NIR irradiation. (E) Corresponding antibacterial rates under different conditions. Reprinted with permission from¹⁴³, Copyright (2025), Springer Nature.

Furthermore, photothermal effects have been integrated with drug-controlled release and enhanced osseointegration for multifunctional therapy. Ji *et al.*¹⁴⁴ constructed an NIR-triggered cascade release system on SLM-printed porous titanium scaffolds. Upon 808 nm laser irradiation, PTT (~54°C) was first induced, leading to rapid degradation of a thermosensitive hydrogel on the surface and the release of Mg²⁺, curcumin, and paclitaxel for early postoperative antitumor, antibacterial, and anti-inflammatory regulation. Meanwhile, ZnO loaded within the scaffold matrix provided long-term Zn²⁺ release, supporting prolonged antibacterial and osteogenic effects. Cai *et al.*¹⁴⁵ demonstrated a sequential therapeutic strategy combining photothermal ablation with long-term therapeutic delivery. A wide-bandgap TiO₂/TiP photothermal coating was constructed on electron beam melting (EBM) printed Ti6Al4V scaffolds, and pores were infused with a gelatin/hyaluronic acid (Gel/HA) release system loaded with the antiresorptive drug alendronate (ALN). Under NIR irradiation, PTT directly ablated residual osteosarcoma cells, while ALN was continuously released (approximately 78% over 28 days), effectively promoting osteogenic differentiation of bone marrow mesenchymal stem cells and in vivo osseointegration. Zhang et

al.¹⁴⁶ developed a rare-earth-doped TiO₂/quercetin/L-arginine (TiO₂@UCN/Qr/LA) composite coating on titanium implants. Under 1060 nm NIR irradiation, the system heated to 48°C and generated reactive oxygen species, which synergized with L-arginine in the coating to produce angiogenesis-promoting nitric oxide (NO) in situ under light exposure. This enabled integrated antibacterial, anti-inflammatory, osteogenic, and angiogenic functions, achieving efficient synergistic therapy.

(ii) Electrically-responsive release strategy

Electrically-responsive strategies construct conductive coatings on implant surfaces, such as polypyrrole (PPy) and polyaniline (PANI). By applying safe external voltages, reversible and precise regulation of surface properties or the state of loaded molecules can be achieved.^{147,148}

Liao *et al.*¹⁴⁹ prepared a PPy coating co-doped with chondroitin sulfate and the antimicrobial peptide OP-145 on Ti-5Al-2.5Fe implants. By switching the polarity of the applied voltage (+0.50 V vs. -0.50 V), functional molecules with different charges could be directionally enriched at the coating surface. Under anodic conditions, OP-145 dominated the surface, providing contact-based antibacterial activity; under cathodic conditions, chondroitin sulfate was exposed, promoting osteoblast adhesion, spreading, and differentiation. This design enabled the same implant to switch functional modes noninvasively via external electrical signals according to postoperative stage requirements.

(iii) Magnetically-responsive strategies

Magnetically-responsive strategies primarily utilize superparamagnetic nanoparticles such as Fe₃O₄ to generate magnetic hyperthermia under an alternating magnetic field (AMF). This mechanism is similar to photothermal therapy, but magnetic fields are less affected by optical scattering and can penetrate deep tissues. However, achieving efficient energy conversion under clinically safe field strengths remains challenging.¹⁵⁰ In addition, magnetic particles can generate magneto-mechanical effects under gradient magnetic fields, directly disrupting bacterial biofilm structures. Static magnetic fields themselves have also been shown to promote bone healing by influencing membrane receptors and ion channels.¹⁵¹ The greatest advantage of magnetic responsiveness is the ability to noninvasively and remotely manipulate implants at virtually any depth within the body.¹⁵²

Zeng *et al.*¹⁵³ constructed an AM porous polymer scaffold integrated with Fe₃O₄ nanoparticles and loaded with a drug-containing thermosensitive hydrogel. This system first used NIR-triggered

PTT to achieve rapid antibacterial action and drug release. After infection control, an externally applied static magnetic field was used to promote endothelial cell tubule formation and migration, enhancing angiogenesis and thereby coupling vascularization with bone tissue regeneration.

Overall, exogenous physical field-triggered systems provide important strategies for achieving spatiotemporally precise regulation of therapeutic release from implants. Unlike endogenous microenvironment-responsive systems that depend on pathological signals, exogenous stimuli such as light, magnetic fields, and electrical stimulation can be applied on demand and dynamically adjusted in intensity and duration according to clinical needs. By converting externally supplied energy into localized physical or chemical changes within carrier materials, these strategies enable noninvasive and repeatable control over therapeutic delivery.

4. Summary and Outlook

4.1 Summary

Overall, AM is driving metallic orthopedic implants from traditional passive load-bearing devices toward multifunctional therapeutic platforms capable of actively participating in bone repair. The significance of this transition lies not only in the geometric flexibility and manufacturing freedom provided by AM, but also in its ability to integrate structural design, bioactive substances, and therapeutic regulation within a single implant system. In this review, major strategies for bioactive integration, including bulk alloying, structural reservoir integration, and surface functionalization, are systematically summarized. These approaches enable implants to achieve antibacterial activity, immunomodulation, osteogenesis promotion, angiogenic regulation, and localized therapeutic delivery through different material and structural pathways. Furthermore, recent advances in controlled-release systems are discussed, particularly stimulus-responsive platforms capable of responding to endogenous pathological cues or exogenous physical stimulation. Collectively, these developments indicate that the design logic of AM metallic implants is gradually shifting from static structural replacement toward dynamically regulated therapeutic systems.

4.2 Existing challenges

Despite substantial progress, several important challenges still limit the further development of bioactive-integrated AM metallic orthopedic implants.

(i) Achieving effective coordination among multiple therapeutic functions remains difficult. Antibacterial activity, osteogenesis promotion, angiogenic regulation, immunomodulation, and controlled release often require different activation periods, concentration ranges, and release kinetics. However, many current systems still rely on simple functional superposition rather than truly coordinated regulation. Similarly, highly porous structures that favor drug loading and tissue ingrowth may simultaneously accelerate degradation or compromise mechanical stability. Therefore, one of the central challenges is how to achieve biologically rational coordination among therapeutic efficacy, release behavior, structural stability, and biosafety within a single implant system.

(ii) The intrinsic characteristics of AM processes introduce additional complexity to bioactive integration systems. Layer-wise fabrication can generate heterogeneous microstructures, surface roughness variations, partially melted particles, and internal defects, all of which may influence coating uniformity, interfacial bonding stability, corrosion behavior, and release consistency. In complex porous architectures, irregular transport pathways and local microenvironment differences may further result in nonuniform loading distribution and unpredictable release behavior. In addition, post-processing procedures may alter surface chemistry and subsequently affect biological performance. As a result, the interactions among printing parameters, structural features, surface properties, and therapeutic functions remain insufficiently understood.

4.3 Future perspectives

(i) Future development of AM metallic orthopedic implants will likely focus on the transition from single-function enhancement toward spatiotemporally coordinated therapeutic systems. Rather than simply integrating multiple bioactive components into one implant, future strategies should aim to achieve sequential and environment-adaptive regulation throughout different stages of bone healing. For example, early-stage antibacterial activity may need to be combined with sustained osteogenic and angiogenic promotion at later stages. Therefore, future implant design may increasingly emphasize therapeutic timing, spatial distribution, and functional coordination.

(ii) Structural design is expected to play a more active role in therapeutic regulation. AM enables precise control over pore geometry, hierarchical architecture, and internal transport pathways, allowing structural features to directly influence diffusion behavior, local mass transport, and therapeutic distribution. Consequently, future AM metallic implants may evolve from drug-

loaded structures toward structure-mediated therapeutic systems, in which architecture itself participates in therapeutic regulation.

(iii) The integration of computational and data-driven approaches is another important direction. Computational simulation, degradation prediction, and AI-assisted parameter optimization may help establish quantitative relationships among material composition, structural configuration, release behavior, and biological response, thereby improving multifunctional implant design and optimization.

Overall, future AM metallic implants will increasingly rely on the synergistic integration of material composition, structural architecture, and therapeutic regulation, enabling next-generation implants to actively participate in complex bone-repair processes.

Acknowledgments

None.

Funding

The authors acknowledge the financial supports from the National Key Research and Development Program of China (Grant No. 2024YFE0109000), the Fundamental Research Funds for the Central Universities (project number YG2024LC04), the Fundamental Research Funds for the Central Universities (Grant No. YG2023QNA21), the Establishment and Application of Traditional Chinese and Western Medicine Collaborative Diagnosis and Treatment Center for Major Difficult Diseases (ZY(2025-2027)-2-1-4), the Three-year Action Plan of Shanghai Municipality for Further Accelerating the Inheritance, the Innovation and Development of Traditional Chinese Medicine: Shanghai High Level Talent Guiding Project in Traditional Chinese Medicine (Grant No. ZY (2021-2023)-0403), the Shanghai Municipal Health Commission Scientific Research project plan (Grant No. 202340059), the Collaborative Traditional Chinese Medicine and Western Medicine Guiding Project of General Hospital (Grant No. ZXXT-202308), the Standardization Project of Traditional Chinese Medicine (2025BZ026), and the 2nd national Western medicine doctor studying TCM excellent talents research plan (2023.6-2026.5).

Conflict of interest

Both Chee Kai Chua and Liqiang Wang serve the Editorial Board of this journal as Editor-in-Chief and Editorial Board Member, respectively, and Liqiang Wang is also the sole Guest Editor of this special issue, but they were not in any way involved in the editorial and peer-review process conducted for this paper, directly or indirectly. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Author contributions

Conceptualization: Yi Mao, Yihong Li, Liqiang Wang, Qi Li

Visualization: Yi Mao, Yihong Li

Writing—original draft: Yi Mao, Yihong Li

Writing—review & editing: All authors

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data

Not applicable.

References

1. Yang C, Fang H, Dou Q, et al. Progress in bone repair scaffolds: Interdisciplinary perspective for mechanism and material design. *Coordination Chemistry Reviews*. 2026;549:217355. doi:<https://doi.org/10.1016/j.ccr.2025.217355>
2. Ma Y, Song X, Luo B, et al. 3D-printed triboelectric scaffolds for fabricating BMSC-derived cartilage to repair bone defects and promote endochondral ossification. *Bioactive Materials*. 2026;58:685-700. doi:<https://doi.org/10.1016/j.bioactmat.2025.11.044>

3. Lu H, Li Z, Duan Z, et al. Photothermal catalytic reduction and bone tissue engineering towards a three - in - one therapy strategy for osteosarcoma. *Advanced Materials*. 2024;36(40):2408016. doi: <https://doi.org/10.1002/adma.202408016>
4. Wang T, Ouyang H, Luo Y, et al. Rehabilitation exercise-driven symbiotic electrical stimulation system accelerating bone regeneration. *Science advances*. 2024;10(1):eadi6799. doi:<https://doi.org/10.1126/sciadv.adi6799>
5. Collon K, Gallo MC, Lieberman JR. Musculoskeletal tissue engineering: regional gene therapy for bone repair. *Biomaterials*. 2021;275:120901. doi:<https://doi.org/10.1016/j.biomaterials.2021.120901>
6. Kinzel M, Kalra A, Tripathi G, Dharmani-Khan P, Khan F, Storek J. Lack of both donor and recipient anti-EBV T cells in EBV seronegative recipients of grafts from seropositive donors. *Bone Marrow Transplantation*. 2023;58(3):332-333. doi:<https://doi.org/10.1038/s41409-022-01884-3>
7. Bai Y, Wu N, Li X, et al. Recent progress of 3D printed responsive scaffolds for bone repair: A review. *Materials Today Bio*. 2025:102351. doi:<https://doi.org/10.1016/j.mtbio.2025.102351>
8. Qin T, Lian X, Ullah A, et al. The multi-scale porous and hydrophilic 3D printed polycaprolactone/silk fibroin/ β -tricalcium phosphate bone scaffolds effect on femoral defect repair. *International Journal of Biological Macromolecules*. 2025:148230. doi:<https://doi.org/10.1016/j.ijbiomac.2025.148230>
9. Lu X, Guo Z, Zhou X, et al. Deformation behavior and corrosion resistance of bio-inspired porous Ti-6Al-4V implants fabricated by selective laser melting. *Powder Technology*. 2026:122147. doi:10.1016/j.powtec.2026.122147
10. Wu X, Jing X, She J, Yuan H, Pan F. The influence of zinc content on degradation control and mechanical behavior of Mg-Zn-Mn alloys for bone implants. *Materials Today Communications*. 2025:113610. doi:<https://doi.org/10.1016/j.mtcomm.2025.113610>
11. Chao L, Chao Q, Feng Q, et al. Design of bionic porous structure of bone scaffolds and analysis of fatigue and permeability characteristics. *Frontiers in Bioengineering and Biotechnology*. 2026;14:1765370. doi:<https://doi.org/10.3389/fbioe.2026.1765370>
12. Shi J, Dai W, Gupta A, et al. Frontiers of hydroxyapatite composites in bionic bone tissue engineering. *Materials*. 2022;15(23):8475. doi:<https://doi.org/10.3390/ma15238475>

13. Cui Y-W, Wang L, Zhang L-C. Towards load-bearing biomedical titanium-based alloys: From essential requirements to future developments. *Progress in Materials Science*. 2024;144:101277. doi:<https://doi.org/10.1016/j.pmatsci.2024.101277>
14. Ouyang L, He X, Liao Y, et al. Electric field stimulation-responsive hydrogels for bone regeneration: from mechanisms to applications. *Bone Research*. 2026;14(1):4. doi:<https://doi.org/10.1038/s41413-025-00482-5>
15. Yan Y, Kang Y, Li D, et al. Microstructure, mechanical properties and corrosion behavior of porous Mg-6 wt.% Zn scaffolds for bone tissue engineering. *Journal of Materials Engineering and Performance*. 2018;27(3):970-984. doi:<https://doi.org/10.1007/s11665-018-3189-x>
16. Zaharin HA, Abdul Rani AM, Azam FI, et al. Effect of Unit Cell Type and Pore Size on Porosity and Mechanical Behavior of Additively Manufactured Ti6Al4V Scaffolds. *Materials*. 2018;11(12):2402. doi:<https://doi.org/10.3390/ma11122402>
17. Tsai C-H, Hung C-H, Kuo C-N, Chen C-Y, Peng Y-N, Shie M-Y. Improved bioactivity of 3D printed porous titanium alloy scaffold with chitosan/magnesium-calcium silicate composite for orthopaedic applications. *Materials*. 2019;12(2):203. doi:<https://doi.org/10.3390/ma12020203>
18. Zhang C, Poudel I, Mita N, et al. Amikacin Coated 3D-Printed Metal Devices for Prevention of Postsurgical Infections (PSIs). *Pharmaceutics*. 2025;17(7):911. doi:<https://doi.org/10.3390/pharmaceutics17070911>
19. Yang Z, Jiang D, Zhou M, et al. Osteoblastic differentiation and antibacterial activity of reduced graphene oxide modified titanium alloy implant surfaces prepared via friction stir processing. *Journal of Materials Science & Technology*. 2025;236:150-162. doi:<https://doi.org/10.1016/j.jmst.2025.03.022>
20. Mahajan A, Devgan S, Kalyanasundaram D. Surface alteration of Cobalt-Chromium and duplex stainless steel alloys for biomedical applications: a concise review. *Materials and Manufacturing Processes*. 2023;38(3):260-270. doi:<https://doi.org/10.1080/10426914.2022.2105873>
21. Yang K, Ren Y. Nickel-free austenitic stainless steels for medical applications. *Science and technology of advanced materials*. 2010;11(1):014105. doi:doi:10.1088/1468-6996/11/1/014105

22. Chen Q, Thouas G. Metallic implant biomaterials. *Materials Science and Engineering R: Reports*. 2015;doi:<https://doi.org/10.1016/j.mser.2014.10.001>
23. Geetha M, Singh AK, Asokamani R, Gogia AK. Ti based biomaterials, the ultimate choice for orthopaedic implants—A review. *Progress in materials science*. 2009;54(3):397-425. doi:<https://doi.org/10.1016/j.pmatsci.2008.06.004>
24. Zhao L, Pei X, Jiang L, et al. Bionic design and 3D printing of porous titanium alloy scaffolds for bone tissue repair. *Composites Part B: Engineering*. 2019;162:154-161. doi:<https://doi.org/10.1016/j.compositesb.2018.10.094>
25. Yaman P, Kucukyildirim BO. Tailoring Ti3C2Tx MXene multilayers for biomaterial integration: synthesis, characterization, and cytotoxicity. *Materials Science and Engineering: B*. 2026;323:118752. doi:<https://doi.org/10.1016/j.mseb.2025.118752>
26. Niu J, Xiong M, Guan X, et al. The in vivo degradation and bone-implant interface of Mg-Nd-Zn-Zr alloy screws: 18 months post-operation results. *Corrosion Science*. 2016;113:183-187. doi:<https://doi.org/10.1016/j.corsci.2016.10.009>
27. Moravej M, Mantovani D. Biodegradable metals for cardiovascular stent application: interests and new opportunities. *International journal of molecular sciences*. 2011;12(7):4250-4270. doi:<https://doi.org/10.3390/ijms12074250>
28. Zhao L, Wang X, Wang T, Xia Y, Cui C. Mechanical properties and biodegradation of porous Zn-1Al alloy scaffolds. *Materials Letters*. 2019;247:75-78. doi:<https://doi.org/10.1016/j.matlet.2019.03.097>
29. Kabir H, Munir K, Wen C, Li Y. Recent research and progress of biodegradable zinc alloys and composites for biomedical applications: Biomechanical and biocorrosion perspectives. *Bioactive materials*. 2021;6(3):836-879. doi:<https://doi.org/10.1016/j.bioactmat.2020.09.013>
30. Gao Y, Jiang W, Zeng D, Liang X, Ma C, Xiao W. Additive manufacturing of titanium alloys for biomedical applications: A systematic review. *Review of Materials Research*. 2025;1(1):100011. doi:<https://doi.org/10.1016/j.revmat.2025.100011>
31. Koju N, Niraula S, Fotovvati B. Additively manufactured porous Ti6Al4V for bone implants: a review. *Metals*. 2022;12(4):687. doi:<https://doi.org/10.3390/met12040687>
32. Dzogbewu T. Additive manufacturing of porous Ti-based alloys for biomedical applications—a review. *Journal for New Generation Sciences*. 2017;15(1):278-294. Available from: <https://hdl.handle.net/10520/EJC-c860d5fab>

33. Nabeel M, Farooq A, Miraj S, Yahya U, Hamad K, Deen K. Comparison of the properties of additively manufactured 316L stainless steel for orthopedic applications: a review. *World Scientific Annual Review of Functional Materials*. 2023;1:2230001. doi:<https://doi.org/10.1142/S281092282230001X>
34. Ara I, Bajwa D, Raeisi A. A review on the wear performance of additively manufactured 316L stainless steel: process, structure, and performance. *Journal of Materials Science*. 2025;60(13):5686-5720. doi:<https://doi.org/10.1007/s10853-025-10775-z>
35. Acharya S, Soni R, Suwas S, Chatterjee K. Additive manufacturing of Co–Cr alloys for biomedical applications: A concise review. *Journal of Materials Research*. 2021;36(19):3746-3760. doi:DOI:10.1557/s43578-021-00244-z
36. Shafizadeh M, Yapici GG. Wear performance of additive-manufactured and heat-treated CoCrMo alloy. *Materials Letters*. 2025:139761. doi:<https://doi.org/10.1016/j.matlet.2025.139761>
37. Aikin M, Shalomeev V, Kukhar V, et al. Recent advances in biodegradable magnesium alloys for medical implants: evolution, innovations, and clinical translation. *Crystals*. 2025;15(8):671. doi:<https://doi.org/10.3390/cryst15080671>
38. Hashemi TS, Jaiswal S, McCarthy HO, Levingstone TJ, Dunne NJ. Biofunctionalisation of porous additively manufactured magnesium-based alloys for orthopaedic applications: a review. *Biomaterials Advances*. 2025;169:214170. doi:10.1016/j.bioadv.2024.214170
39. Gracheva A, Polozov I, Popovich A. Additive manufacturing of biodegradable metallic implants by selective laser melting: current research status and application perspectives. *Metals*. 2025;15(7):754. doi:<https://doi.org/10.3390/met15070754>
40. Yang X, Peng Z, Fang Y, Tang Y, Shen H-H, Zhu Y. Review of additively manufactured zinc alloys by laser powder bed fusion for biomedical applications: X. Yang et al. *Rare Metals*. 2025;44(11):8262-8291. doi:<https://doi.org/10.1007/s12598-025-03518-1>
41. Wang J, Zhang Y, Huang W, et al. Biodegradable porous zinc scaffolds for bone regeneration: multiscale architecture, degradation control, and osteo-immunomodulation. *Current Opinion in Solid State and Materials Science*. 2026;42:101270. doi:<https://doi.org/10.1016/j.cossms.2026.101270>

42. Chua K, Khan I, Malhotra R, Zhu D. Additive manufacturing and 3D printing of metallic biomaterials. *Engineered Regeneration*. 2021;2:288-299. doi:<https://doi.org/10.1016/j.engreg.2021.11.002>
43. Li Y, Jiang D, Zhu R, Yang C, Wang L, Zhang L-C. Revolutionizing medical implant fabrication: advances in additive manufacturing of biomedical metals. *International Journal of Extreme Manufacturing*. 2025;7(2):022002. doi:10.1088/2631-7990/ad92cc
44. Wang B, Zhou C, Zhou J, et al. Niti minimal surface porous scaffolds matching human bone characteristics: mechanical, permeability and osteogenic properties. *Virtual and Physical Prototyping*. 2026;21(1):e2633475. doi:10.1080/17452759.2026.2633475
45. Ardila L, Garciandia F, González-Díaz J, et al. Effect of IN718 recycled powder reuse on properties of parts manufactured by means of selective laser melting. *Physics Procedia*. 2014;56:99-107. doi:<https://doi.org/10.1016/j.phpro.2014.08.152>
46. Wauthle R, Van der Stok J, Yavari SA, et al. Additively manufactured porous tantalum implants. *Acta biomaterialia*. 2015;14:217-225. doi:<http://dx.doi.org/10.1016/j.actbio.2014.12.003>
47. Mazzoli A. Selective laser sintering in biomedical engineering. *Medical & biological engineering & computing*. 2013;51(3):245-256. doi:<https://doi.org/10.1007/s11517-012-1001-x>
48. Zhao X, Li S, Zhang M, et al. Comparison of the microstructures and mechanical properties of Ti-6Al-4V fabricated by selective laser melting and electron beam melting. *Materials & Design*. 2016;95:21-31. doi:<http://dx.doi.org/10.1016/j.matdes.2015.12.135>
49. Zaharin HA, Abdul Rani AM, Ginta TL, Azam FI. Additive Manufacturing Technology for Biomedical Components: A review. *IOP Conference Series: Materials Science and Engineering*. 2018;328(1):012003. doi:10.1088/1757-899X/328/1/012003
50. Hong D, Chou D-T, Velikokhatnyi OI, et al. Binder-jetting 3D printing and alloy development of new biodegradable Fe-Mn-Ca/Mg alloys. *Acta biomaterialia*. 2016;45:375-386. doi:<http://dx.doi.org/10.1016/j.actbio.2016.08.032>
51. Shakor P, Chu S, Puzatova A, Dini E. Review of binder jetting 3D printing in the construction industry. *Progress in Additive Manufacturing*. 2022;7(4):643-669. doi:<https://doi.org/10.1007/s40964-021-00252-9>

52. Putra N, Leeftang M, Minneboo M, et al. Extrusion-based 3D printed biodegradable porous iron. *Acta Biomaterialia*. 2021;121:741-756. doi:<https://doi.org/10.1016/j.actbio.2020.11.022>
53. Zhang H, Sun H, Zhang L, et al. Coaxial 3D printing scaffolds with sequential antibacterial and osteogenic functions to effectively repair infected mandibular defects. *Advanced Functional Materials*. 2024;34(44):2407483. doi:<https://doi.org/10.1002/adfm.202407483>
54. Zhu Y, Dai B, Li X, et al. Periosteum-inspired membranes integrated with bioactive magnesium oxychloride ceramic nanoneedles for guided bone regeneration. *ACS applied materials & interfaces*. 2022;14(35):39830-39842. doi:<https://doi.org/10.1021/acsami.2c10615>
55. Hu W, Mao T, Chen J, et al. Robust adhesive, antibacterial, pro-angiogenic and osteogenic bone adhesives with moderate degradability facilitating bone regeneration. *Bioactive Materials*. 2026;56:353-367. doi:<https://doi.org/10.1016/j.bioactmat.2025.08.031>
56. Jing Z, Zhang T, Xiu P, et al. Functionalization of 3D-printed titanium alloy orthopedic implants: a literature review. *Biomedical Materials*. 2020;15(5):052003. doi:10.1088/1748-605X/ab9078
57. Vyavahare S, Mahesh V, Mahesh V, Harursampath D. Additively manufactured meta-biomaterials: A state-of-the-art review. *Composite Structures*. 2023;305:116491. doi:<https://doi.org/10.1016/j.compstruct.2022.116491>
58. Kechagias S, Munford MJ, Masure FCH, van Arkel RJ, Oosterbeek RN. Lattice Structures for Bone Replacement: The Intersection of Bone Biomechanics, Lattice Design, and Additive Manufacturing. *Advanced Materials Technologies*. 2026;n/a(n/a):e01885. doi:<https://doi.org/10.1002/admt.202501885>
59. Li J, Zheng Y, Yu Z, et al. Surface-modified titanium and titanium-based alloys for improved osteogenesis: A critical review. *Heliyon*. 2024;10(1)doi:10.1016/j.heliyon.2023.e23779
60. Akay S, Yaghmur A. Recent Advances in Antibacterial Coatings to Combat Orthopedic Implant-Associated Infections. *Molecules*. 2024;29(5):1172. doi:10.3390/molecules29051172
61. Zhang B, Lu D, Duan H. Recent advances in responsive antibacterial materials: design and application scenarios. *Biomater Sci*. 2023;11(2):356-379. doi:10.1039/d2bm01573k

62. Mullins ND, Deadman BJ, Moynihan HA, et al. The impact of storage conditions upon gentamicin coated antimicrobial implants. *Journal of Pharmaceutical Analysis*. 2016;6(6):374-381. doi:<https://doi.org/10.1016/j.jpha.2016.05.002>
63. Gordon O, Lee DE, Liu B, et al. Dynamic PET-facilitated modeling and high-dose rifampin regimens for Staphylococcus aureus orthopedic implant-associated infections. *Science Translational Medicine*. 13(622):eabl6851. doi:10.1126/scitranslmed.abl6851
64. Wehrli W. Rifampin: mechanisms of action and resistance. *Rev Infect Dis*. 1983;5(Suppl 3):S407-11. doi:10.1093/clinids/5.supplement_3.s407
65. Zhang C, Li J, Lin L, et al. The impact of rifampin on the efficacy of implant retention and prosthesis removal in staphylococcal periprosthetic joint infection. Original Research. *Frontiers in Cellular and Infection Microbiology*. 2025;15. doi:10.3389/fcimb.2025.1587436
66. Mohamed W, Sommer U, Sethi S, et al. Intracellular proliferation of S. aureus in osteoblasts and effects of rifampicin and gentamicin on S. aureus intracellular proliferation and survival. *Eur Cell Mater*. 2014;28:258-268. doi:10.22203/eCM.v028a18
67. Kobata SI, Teixeira LEM, Fernandes SOA, Faraco AAG, Vidigal PVT, Araújo ID. Prevention of bone infection after open fracture using a chitosan with ciprofloxacin implant in animal model. *Acta Cir Bras*. 2020;35(8):e202000803. doi:10.1590/s0102-8650202000800000003
68. Tan H, Ma R, Lin C, Liu Z, Tang T. Quaternized Chitosan as an Antimicrobial Agent: Antimicrobial Activity, Mechanism of Action and Biomedical Applications in Orthopedics. *International Journal of Molecular Sciences*. 2013;14(1):1854-1869. doi:10.3390/ijms14011854
69. Zapata ME, Tovar CD, Hernandez JH. The Role of Chitosan and Graphene Oxide in Bioactive and Antibacterial Properties of Acrylic Bone Cements. *Biomolecules*. 2020;10(12):1616. doi:10.3390/biom10121616
70. Ke C-L, Deng F-S, Chuang C-Y, Lin C-H. Antimicrobial Actions and Applications of Chitosan. *Polymers*. 2021;13(6):904. doi:10.3390/polym13060904
71. Costa B, Martínez-de-Tejada G, Gomes PAC, L. Martins MC, Costa F. Antimicrobial Peptides in the Battle against Orthopedic Implant-Related Infections: A Review. *Pharmaceutics*. 2021;13(11):1918. doi:10.3390/pharmaceutics13111918

72. Ageitos JM, Sánchez-Pérez A, Calo-Mata P, Villa TG. Antimicrobial peptides (AMPs): Ancient compounds that represent novel weapons in the fight against bacteria. *Biochemical Pharmacology*. 2017;133:117-138. doi:<https://doi.org/10.1016/j.bcp.2016.09.018>
73. Batoni G, Maisetta G, Esin S. Antimicrobial peptides and their interaction with biofilms of medically relevant bacteria. *Biochim Biophys Acta*. 2016;1858(5):1044-60. doi:10.1016/j.bbamem.2015.10.013
74. Pletzer D, Coleman SR, Hancock RE. Anti-biofilm peptides as a new weapon in antimicrobial warfare. *Curr Opin Microbiol*. 2016;33:35-40. doi:10.1016/j.mib.2016.05.016
75. Burla A, Khandelwal M, Vaidya M. Antibacterial properties of Cu containing complex concentrated alloys. *Materials Today Communications*. 2022;33:104915. doi:<https://doi.org/10.1016/j.mtcomm.2022.104915>
76. Zou Y-H, Wang J, Cui L-Y, et al. Corrosion resistance and antibacterial activity of zinc-loaded montmorillonite coatings on biodegradable magnesium alloy AZ31. *Acta Biomaterialia*. 2019;98:196-214. doi:<https://doi.org/10.1016/j.actbio.2019.05.069>
77. Pareek V, Gupta R, Panwar J. Do physico-chemical properties of silver nanoparticles decide their interaction with biological media and bactericidal action? A review. *Mater Sci Eng C Mater Biol Appl*. 2018;90:739-749. doi:10.1016/j.msec.2018.04.093
78. Qing Y, Cheng L, Li R, et al. Potential antibacterial mechanism of silver nanoparticles and the optimization of orthopedic implants by advanced modification technologies. *Int J Nanomedicine*. 2018;13:3311-3327. doi:10.2147/ijn.S165125
79. Dai Q, Zong Y, Zhu J, et al. A chronological regulated implant coating with antibacterial and osteogenesis constructed by TA-mediated LbL self-assembly. *Materials & Design*. 2024;241:112897. doi:<https://doi.org/10.1016/j.matdes.2024.112897>
80. Gui X, Zhang B, Qin Y, et al. Structural and material double mechanical enhancement of HAp scaffolds promote bone defect regeneration. *Composites Part A: Applied Science and Manufacturing*. 2025;189:108600. doi:<https://doi.org/10.1016/j.compositesa.2024.108600>
81. Pajarinen J, Cenni E, Savarino L, et al. Profile of toll-like receptor-positive cells in septic and aseptic loosening of total hip arthroplasty implants. *J Biomed Mater Res A*. 2010;94(1):84-92. doi:10.1002/jbm.a.32674

82. El Bialy I, Jiskoot W, Reza Nejadnik M. Formulation, Delivery and Stability of Bone Morphogenetic Proteins for Effective Bone Regeneration. *Pharm Res.* 2017;34(6):1152-1170. doi:10.1007/s11095-017-2147-x
83. Wozney JM. Bone Morphogenetic Proteins. *Progress in Growth Factor Research.* 1989;1(4):267-280. doi:[https://doi.org/10.1016/0955-2235\(89\)90015-X](https://doi.org/10.1016/0955-2235(89)90015-X)
84. Berten-Schunk L, Roger Y, Bunjes H, Hoffmann A. Release of TGF- β 3 from Surface-Modified PCL Fiber Mats Triggers a Dose-Dependent Chondrogenic Differentiation of Human Mesenchymal Stromal Cells. *Pharmaceutics.* 2023;15(4):1303. doi:10.3390/pharmaceutics15041303
85. Grosso A, Lunger A, Burger MG, et al. VEGF dose controls the coupling of angiogenesis and osteogenesis in engineered bone. *npj Regenerative Medicine.* 2023;8(1):15. doi:10.1038/s41536-023-00288-1
86. Guo Y, Jin X, Xiong W, Tan W, Zhou Y. Restoration of vasculogenic microtissue sprouting in osteogenic niches using PDGF-BB for prevascularized bone engineering. *Tissue and Cell.* 2026;98:103168. doi:<https://doi.org/10.1016/j.tice.2025.103168>
87. Bai H, Cui Y, Wang C, et al. 3D printed porous biomimetic composition sustained release zoledronate to promote osteointegration of osteoporotic defects. *Materials & Design.* 2020;189:108513. doi:<https://doi.org/10.1016/j.matdes.2020.108513>
88. Zhu C, Jia Y, Tang Y, et al. Functionalized chitosan hydrogel promotes osseointegration at the interface of 3D printed titanium alloy scaffolds. *International Journal of Biological Macromolecules.* 2024;266:131169. doi:<https://doi.org/10.1016/j.ijbiomac.2024.131169>
89. Li S, Cui Y, Liu H, et al. Dual-functional 3D-printed porous bioactive scaffold enhanced bone repair by promoting osteogenesis and angiogenesis. *Materials Today Bio.* 2024;24:100943. doi:<https://doi.org/10.1016/j.mtbio.2024.100943>
90. Chu F, Wang Z, Zhang D, et al. Research on the osteogenic properties of 3D-printed porous titanium alloy scaffolds loaded with Gelma/PAAM-ZOL composite hydrogels. *International Journal of Biological Macromolecules.* 2024;276:134050. doi:<https://doi.org/10.1016/j.ijbiomac.2024.134050>
91. Baek J, Moon W, Chung SH, Kim B-S. Injectable ABA Triblock Copolyether Hydrogel for Dental Implant-Mediated Drug Delivery. *Biomacromolecules.* 2026;27(1):930-937. doi:10.1021/acs.biomac.5c02307

92. Sheng X, Che Z, Qiao H, et al. A functional mineralized collagen hydrogel to promote angiogenic and osteogenic for osseointegration of 3D-printed titanium alloy microporous scaffolds. *International Journal of Biological Macromolecules*. 2024;277:133806. doi:<https://doi.org/10.1016/j.ijbiomac.2024.133806>
93. Wang Y, Wang Y, Yu L, et al. Collagen-Coated 3D-Printed Magnesium Alloy Scaffold with Controlled Mg²⁺ Release for Enhanced Repair of Critical-Sized Bone Defects. *ACS Applied Materials & Interfaces*. 2025;17(45):61760-61774. doi:10.1021/acsami.5c16661
94. Wu L, Pei X, Dou Q, et al. 3D Printed Calcium Phosphate Physiochemically Dual-Regulating Pro-Osteogenesis and Antiosteolysis for Enhancing Bone Tissue Regeneration. *ACS Applied Materials & Interfaces*. 2024;16(28):37007-37016. doi:10.1021/acsami.4c06318
95. Knaislová A, Horkavcová D, Jablonská E, Vojtěch D. Sol-gel TiO₂-based coatings in 3D printed porous Ti-6Al-4V alloy structures as efficient antibacterial drug delivery systems: Thorough structural and biological characterization. *Applied Surface Science Advances*. 2025;29:100816. doi:<https://doi.org/10.1016/j.apsadv.2025.100816>
96. Tabia Z, Bricha M, El Mabrouk K, Vaudreuil S. Manufacturing of a metallic 3D framework coated with a bioglass matrix for implant applications. *Journal of Materials Science*. 2021;56(2):1658-1672. doi:10.1007/s10853-020-05370-3
97. Ye J, Miao B, Xiong Y, et al. 3D printed porous magnesium metal scaffolds with bioactive coating for bone defect repair: enhancing angiogenesis and osteogenesis. *Journal of Nanobiotechnology*. 2025;23(1):160. doi:10.1186/s12951-025-03222-3
98. Zhao Z, Ma S, Wu C, et al. Chimeric Peptides Quickly Modify the Surface of Personalized 3D Printing Titanium Implants to Promote Osseointegration. *ACS Applied Materials & Interfaces*. 2021;13(29):33981-33994. doi:10.1021/acsami.1c11207
99. Migita. S, Sakashita. K, Saito. Y, Suyalatu., Yamazaki. T. Co–Cr–Mo alloy binding peptide as molecular glue for constructing biomedical surfaces. *Journal of Applied Biomaterials & Functional Materials*. 2020;18. doi:10.1177/2280800020924739
100. Cui C, Zhao Y, Yan J, et al. Peptide platform for 3D-printed Ti implants with synergistic antibacterial and osteogenic functions to enhance osseointegration. *Materials Today Bio*. 2025;30:101430. doi:<https://doi.org/10.1016/j.mtbio.2024.101430>
101. Lei H, Cao H, Chen X, et al. A Functionalized 3D-Printed Ti6Al4V “Cell Climbing Frame” Inspired by Marine Sponges to Recruit and Rejuvenate Autologous BMSCs in Osteoporotic

- Bone Repair. *Advanced Materials*. 2025;37(11):2413238. doi:<https://doi.org/10.1002/adma.202413238>
102. Chen Z, Wang B, Yang C, et al. 3D Printed Pedicle Screws with Microarc Oxidation Ceramic Interfaces Enhance Osteointegration and Orthopedic Fixation Feasibility. *ACS Applied Materials & Interfaces*. 2024;16(25):31983-31996. doi:10.1021/acsami.4c03628
 103. Chen H-B, Cui L-Y, Liu W-N, et al. In vitro degradation, antibacterial activity and drug release of levofloxacin-loaded coatings on Mg alloy AZ31: The effect of chain length. *Progress in Organic Coatings*. 2024;189:108327. doi:<https://doi.org/10.1016/j.porgcoat.2024.108327>
 104. Sun J, Liu SS, Zou D, et al. A novel porous interbody fusion cage modified by microarc oxidation and hydrothermal treatment technology accelerate osseointegration and spinal fusion in sheep. *RSC Adv*. 2024;14(44):31966-31978. doi:10.1039/d3ra08185k
 105. Xiu P, Jia Z, Lv J, et al. Tailored Surface Treatment of 3D Printed Porous Ti6Al4V by Microarc Oxidation for Enhanced Osseointegration via Optimized Bone In-Growth Patterns and Interlocked Bone/Implant Interface. *ACS Applied Materials & Interfaces*. 2016;8(28):17964-17975. doi:10.1021/acsami.6b05893
 106. Yang X, Wu L, Li C, et al. Synergistic Amelioration of Osseointegration and Osteoimmunomodulation with a Microarc Oxidation-Treated Three-Dimensionally Printed Ti-24Nb-4Zr-8Sn Scaffold via Surface Activity and Low Elastic Modulus. *ACS Applied Materials & Interfaces*. 2024;16(3):3171-3186. doi:10.1021/acsami.3c16459
 107. Yue X, Xu K, Wang S, et al. SLM Magnesium Alloy Micro-Arc Oxidation Coating. *Materials*. 2024;17(20):4988. doi:10.3390/ma17204988
 108. Fazel M, Salimijazi HR, Shamanian M, et al. Osteogenic and antibacterial surfaces on additively manufactured porous Ti-6Al-4V implants: Combining silver nanoparticles with hydrothermally synthesized HA nanocrystals. *Materials Science and Engineering: C*. 2021;120:111745. doi:<https://doi.org/10.1016/j.msec.2020.111745>
 109. van Hengel IAJ, Riool M, Fratila-Apachitei LE, et al. Selective laser melting porous metallic implants with immobilized silver nanoparticles kill and prevent biofilm formation by methicillin-resistant *Staphylococcus aureus*. *Biomaterials*. 2017;140:1-15. doi:<https://doi.org/10.1016/j.biomaterials.2017.02.030>

110. Yao S, Jiang D, Uglov VV, Ma F, Chen Y, Wang L. Comprehensive review on additive manufacturing of porous biomedical titanium alloys: Structural design, surface modification and applications. *Int J Bioprint*. 2026;12(3):026160143. doi:10.36922/ijb026160143
111. Zhang Z, Li Y, He P, et al. Nanotube-decorated hierarchical tantalum scaffold promoted early osseointegration. *Nanomedicine: Nanotechnology, Biology and Medicine*. 2021;35:102390. doi:<https://doi.org/10.1016/j.nano.2021.102390>
112. Zhao P, Liu Y, Li T, et al. 3D printed titanium scaffolds with ordered TiO₂ nanotubular surface and mesoporous bioactive glass for bone repair. *Progress in Natural Science: Materials International*. 2020;30(4):502-509. doi:<https://doi.org/10.1016/j.pnsc.2020.08.009>
113. Ran Z, Zhao B, Luo D, et al. Promotion of osteogenic differentiation and bone healing in tantalum-coated 3D-printed Ti6Al4V alloy scaffolds using chemical vapor deposition. *Materials & Design*. 2025;258:114722. doi:<https://doi.org/10.1016/j.matdes.2025.114722>
114. Guo Y, Ren L, Xie K, et al. Functionalized TiCu/Ti-Cu-N-Coated 3D-Printed Porous Ti6Al4V Scaffold Promotes Bone Regeneration through BMSC Recruitment. *Advanced Materials Interfaces*. 2020;7(6):1901632. doi:<https://doi.org/10.1002/admi.201901632>
115. Hu Y, Lei H, Tan Z, et al. Silver-doped diamond-like carbon antibacterial coating for 3D-printed titanium alloy total joint implants: Fabrication, characterization and biological function evaluation. *Journal of Materials Research and Technology*. 2025;39:8707-8717. doi:<https://doi.org/10.1016/j.jmrt.2025.11.099>
116. Brodie EG, Robinson KJ, Sigston E, Molotnikov A, Frith JE. Osteogenic Potential of Additively Manufactured TiTa Alloys. *ACS Applied Bio Materials*. 2021;4(1):1003-1014. doi:10.1021/acsabm.0c01450
117. Li J, Cao F, Chen X, et al. Additively manufactured Tantalum-titanium alloys with optimized osteogenic and immunomodulatory properties for load-bearing orthopedic implants. *Bioactive Materials*. 2026;58:49-69. doi:<https://doi.org/10.1016/j.bioactmat.2025.11.029>
118. Liang H, Zhao D, Feng X, et al. 3D-printed porous titanium scaffolds incorporating niobium for high bone regeneration capacity. *Materials & Design*. 2020;194:108890. doi:<https://doi.org/10.1016/j.matdes.2020.108890>
119. Liu A, Zhang Z, Liang Y, et al. Magnesium-induced strengthening, degradation and osteogenesis for additively manufactured Zn-Mg orthopedic implants. *Acta Biomaterialia*. 2025;197:495-506. doi:<https://doi.org/10.1016/j.actbio.2025.03.025>

120. Qin Y, Liu A, Guo H, et al. Additive manufacturing of Zn-Mg alloy porous scaffolds with enhanced osseointegration: In vitro and in vivo studies. *Acta Biomaterialia*. 2022;145:403-415. doi:<https://doi.org/10.1016/j.actbio.2022.03.055>
121. Xu X, Lu Y, Yang X, et al. Copper-Modified Ti6Al4 V Suppresses Inflammatory Response and Osteoclastogenesis while Enhancing Extracellular Matrix Formation for Osteoporotic Bone Regeneration. *ACS Biomaterials Science & Engineering*. 2018;4(9):3364-3373. doi:10.1021/acsbiomaterials.8b00736
122. Xu D, Chen W, Lu Y, et al. 3D-printed Cu-bearing titanium alloy crowns for pediatric oral health: biocompatibility, antibacterial activity, and internal fit. *Journal of Advanced Research*. 2025;doi:<https://doi.org/10.1016/j.jare.2025.12.024>
123. Jiang D, Xie L, Wang L. Current application status of multi-scale simulation and machine learning in research on high-entropy alloys. *Journal of Materials Research and Technology*. 2023;26:1341-1374. doi:<https://doi.org/10.1016/j.jmrt.2023.07.233>
124. Jiang D, Luo M, Liu C, et al. 3D Printing parameter optimisation combined with heat treatment for achieving high density and enhanced performance in refractory high-entropy alloys. *Virtual and Physical Prototyping*. 2025;20(1):e2524524. doi:10.1080/17452759.2025.2524524
125. Mao Y, Jiang D, Vladimir U, Jing Z, Wang L. Machine learning-driven additive manufacturing of biomedical metals: A review of forward prediction, inverse optimization, and quality control. *Eng Sci Add Manuf*. 2025;1(4)doi:10.36922/esam025440031
126. Peng P, Peng Y, Liu F, et al. Bayesian optimization and explainable machine learning for High-dimensional multi-objective optimization of biodegradable magnesium alloys. *Journal of Materials Science & Technology*. 2025;238:132-145. doi:<https://doi.org/10.1016/j.jmst.2025.02.059>
127. Marković G, Manojlović V, Ružić J, Sokić M. Predicting Low-Modulus Biocompatible Titanium Alloys Using Machine Learning. *Materials*. 2023;16(19):6355. doi:10.3390/ma16196355
128. Mukherjee R, Datta S. Materials Informatics Driven Designing Mg Alloys for Biodegradable Short-Term Implants Using Machine Learning. *JOM*. 2025;77(1):20-38. doi:10.1007/s11837-024-06924-5

129. Šalandová M, Leeﬂang MA, Klimopoulou M, Fratila-Apachitei LE, Apachitei I, Zadpoor AA. On-Demand Magnetically-Activated Drug Delivery from Additively Manufactured Porous Bone Implants to Tackle Antibiotic-Resistant Infections. *Advanced Materials Technologies*. 2024;9(8):2301616. doi:<https://doi.org/10.1002/admt.202301616>
130. Karavasili C, Boyce H, Blanco J, et al. 3D-printed antibiotic-eluting pedicle screws for antimicrobial prophylaxis in instrumented spinal fusion. *Cell Reports Physical Science*. 2024;5(12):102320. doi:<https://doi.org/10.1016/j.xcrp.2024.102320>
131. Fan D, Zhang C, Wang H, et al. Fabrication of a composite 3D-printed titanium alloy combined with controlled in situ drug release to prevent osteosarcoma recurrence. *Materials Today Bio*. 2023;20:100683. doi:<https://doi.org/10.1016/j.mtbio.2023.100683>
132. Pereira MMA, Piazza RD, Barbugli PA, et al. Targeted Infection Control and Tissue Integration via pH-Sensitive Smart Coatings on Implant Surfaces. *ACS Applied Materials & Interfaces*. 2026;18(1):2584-2603. doi:10.1021/acsami.5c19344
133. Zhou W, Bai T, Wang L, et al. Biomimetic AgNPs@antimicrobial peptide/silk fibroin coating for infection-trigger antibacterial capability and enhanced osseointegration. *Bioactive Materials*. 2023;20:64-80. doi:<https://doi.org/10.1016/j.bioactmat.2022.05.015>
134. Zhang F, Hu Q, Wei Y, et al. Surface modification of titanium implants by pH-Responsive coating designed for Self-Adaptive antibacterial and promoted osseointegration. *Chemical Engineering Journal*. 2022;435:134802. doi:<https://doi.org/10.1016/j.cej.2022.134802>
135. Zeng Y, Sun C, Yu Z, Zhang K, Nie P, Wang C. Microsphere-Coated Drug Reservoirs in Titanium Implants with pH-Responsive and Osmolality-Adaptive Drug Release for Enhanced Antibacterial Efficacy and Biocompatibility. *ACS Applied Materials & Interfaces*. 2025;17(47):64193-64202. doi:10.1021/acsami.5c16548
136. Li Z, Zhao Y, Wang Z, et al. Engineering Multifunctional Hydrogel-Integrated 3D Printed Bioactive Prosthetic Interfaces for Osteoporotic Osseointegration. *Advanced Healthcare Materials*. 2022;11(11):2102535. doi:<https://doi.org/10.1002/adhm.202102535>
137. Sutrisno L, Hu Y, Shen X, et al. Fabrication of hyaluronidase-responsive biocompatible multilayers on BMP2 loaded titanium nanotube for the bacterial infection prevention. *Materials Science and Engineering: C*. 2018;89:95-105. doi:<https://doi.org/10.1016/j.msec.2018.03.024>

138. Yuan Z, Huang S, Lan S, et al. Surface engineering of titanium implants with enzyme-triggered antibacterial properties and enhanced osseointegration in vivo. 10.1039/C8TB01918E. *Journal of Materials Chemistry B*. 2018;6(48):8090-8104. doi:10.1039/C8TB01918E
139. Yu Y, Ran Q, Shen X, Zheng H, Cai K. Enzyme responsive titanium substrates with antibacterial property and osteo/angio-genic differentiation potentials. *Colloids and Surfaces B: Biointerfaces*. 2020;185:110592. doi:<https://doi.org/10.1016/j.colsurfb.2019.110592>
140. Chen M, Li M, Ren X, et al. DNAzyme Nanoconstruct-Integrated Autonomously-Adaptive Coatings Enhance Titanium-Implant Osteointegration by Cooperative Angiogenesis and Vessel Remodeling. *ACS Nano*. 2023;17(16):15942-15961. doi:10.1021/acsnano.3c04049
141. Bashiru M, Macchi S, Forson M, et al. Doxorubicin-Based Ionic Nanomedicines for Combined Chemo-Phototherapy of Cancer. *ACS Applied Nano Materials*. 2024;7(2):2176-2189. doi:10.1021/acsanm.3c05464
142. Lange N, Szlasa W, Saczko J, Chwiłkowska A. Potential of Cyanine Derived Dyes in Photodynamic Therapy. *Pharmaceutics*. 2021;13(6):818. doi:10.3390/pharmaceutics13060818
143. Wang M-K, Xiao F, Xu X. Antibacterial properties and biological activity of 3D-printed titanium alloy implants with a near-infrared photoresponsive surface. *International Journal of Implant Dentistry*. 2025;11(1):3. doi:10.1186/s40729-024-00587-2
144. Ji Z, Wan Y, Zou Y, Wang H, Liang X, Liu P. Dual-release 3D-printed porous Ti-6Al-4V implant with drug-eluting photothermal micro-nanotopographies: combating osteosarcoma recurrence, infections, and enhancing osteogenesis. *Biomaterials*. 2026;327:123749. doi:<https://doi.org/10.1016/j.biomaterials.2025.123749>
145. Cai B, Huang L, Wang J, et al. 3D Printed Multifunctional Ti6Al4V-Based Hybrid Scaffold for the Management of Osteosarcoma. *Bioconjugate Chemistry*. 2021;32(10):2184-2194. doi:10.1021/acs.bioconjchem.1c00367
146. Zhang G, Wu Z, Yang Y, et al. A multifunctional antibacterial coating on bone implants for osteosarcoma therapy and enhanced osteointegration. *Chemical Engineering Journal*. 2022;428:131155. doi:<https://doi.org/10.1016/j.cej.2021.131155>

147. Mah C, Fraites TJ, Zolotukhin I, et al. Improved Method of Recombinant AAV2 Delivery for Systemic Targeted Gene Therapy. *Molecular Therapy*. 2002;6(1):106-112. doi:<https://doi.org/10.1006/mthe.2001.0636>
148. Wang Y, Rouabhia M, Zhang Z. Pulsed electrical stimulation benefits wound healing by activating skin fibroblasts through the TGF β 1/ERK/NF- κ B axis. *Biochimica et Biophysica Acta (BBA) - General Subjects*. 2016;1860(7):1551-1559. doi:<https://doi.org/10.1016/j.bbagen.2016.03.023>
149. Liao J, Chen W, Yang M, et al. Conducting photopolymers on orthopedic implants having a switch of priority between promoting osteogenic and antibacterial activity. *Materials Horizons*. 2018;5(3):545-552. doi:10.1039/C8MH00285A
150. Kuang Y, Chen S-X, Chen H. Responsive nanoplateforms: Versatile design strategies for efficient cancer theranostics. *Materials & Design*. 2023;232:112076. doi:<https://doi.org/10.1016/j.matdes.2023.112076>
151. Campbell S, Preciado Rivera N, Said S, et al. Injectable On-Demand Pulsatile Drug Delivery Hydrogels Using Alternating Magnetic Field-Triggered Polymer Glass Transitions. *ACS Applied Materials & Interfaces*. 2023;15(42):48892-48902. doi:10.1021/acsami.3c09299
152. Li F, Qin Y, Lee J, et al. Stimuli-responsive nano-assemblies for remotely controlled drug delivery. *Journal of Controlled Release*. 2020;322:566-592. doi:<https://doi.org/10.1016/j.jconrel.2020.03.051>
153. Zeng D, Wang H, Yu Z, et al. Near-infrared light and magnetic field dual-responsive 3D printed scaffolds for sequential treatment of infected bone defects. *Biofabrication*. 2025;17(3):035031. doi:10.1088/1758-5090/adebb3